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Our skin, particularly the barrier provided by the epidermis, functions as our primary 
protection from the harsh environment. It protects us from dangerous pathogens, allergens, 
ultraviolet radiation, and mechanical injury, as well as playing a major role in fluid and 
thermal regulation. Disruption of skin functions can lead to life-threatening consequences 
due to increased risk of infection, trans-epidermal water loss, and allergen sensitization. 
Many common skin disorders often result in a disrupted skin barrier placing patients at risk 
of complications. 
Retinoic acid (RA) is a major component of the vitamin A pathway, which critically 
controls multiple skin functions including cell proliferation and differentiation, barrier 
maintenance and immune regulation. Retinoid-based therapies have successfully been used 
to treat various skin disorders, such as ichthyosis and Darier’s disease, however, the 
prevalence of adverse effects, including dry skin, irritation, redness, photosensitivity, and 
barrier dysregulation, can result in complications and poor compliance. Novel, selective, 
retinoic acid metabolism blocking agents (RAMBAs), intended to minimize adverse 
effects and improve patient outcomes, have been designed and synthesized by our lab. 
In these studies, we first investigated whether our novel RAMBA, DX314, can potentiate 
the effects of RA, via inhibition of the RA-metabolizing enzyme, CYP26B1, in healthy 
human epidermis models. By studying the gene expression effects of RA, DX314, and two 
previous-generation RAMBAs (liarozole and talarozole), we show that DX314 does 
potentiate the effects of RA. Additionally, by studying its effect on epidermal histology 
and transepithelial electrical resistance, we discovered that DX314 displays a unique skin 
barrier-reinforcing property. In our second series of studies, we investigated DX314’s 
therapeutic potential in Darier’s disease and ichthyosis. These results confirm DX314’s 
ability to potentiate RA, and its barrier-reinforcing properties, in diseased skin models and 
suggest that DX314 has potential as a novel therapeutic agent for keratinization disorders. 
Together, the studies within this dissertation show our next-generation RAMBA, DX314, 
is a strong candidate for further drug development in the context of keratinization disorders. 
If successful, DX314 could fulfill the therapeutic need for an efficacious, selective 
RAMBA, providing improved patient outcomes and quality of life, with greatly reduced 
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1.1 HUMAN SKIN 
Our skin primarily functions as a critical barrier between our internal tissues and 
the harsh external environment. It provides protections against pathogens, allergens, 
ultraviolet (UV) radiation, mechanical and chemical insults, as well as playing a major role 
in fluid regulation and thermal homeostasis. Beyond the protective nature of the skin, it 
also provides important sensory (tactile feedback via dermal nerve endings), metabolic 
(vitamin D synthesis), and energy storage functions (subcutaneous adipocytes)1. 
Disruption of these critical skin functions, whether by disease pathology or physical 
destruction (e.g. severe burns, abrasions), can result in major complications for patients. 
These consequences include increased risk of infection, trans-epidermal water loss 
(TEWL), and allergen sensitization2–4. 
Figure 1.1: Illustration of 
primary skin structures. 
Including the hypodermis 
(subcutaneous fat), dermis, 
epidermis, and other major skin 
structures such as sebaceous 
glands, hair follicles, and sweat 
glands.  
Source: Graham-Brown et al. 
(2016), with permission from 




1.1.1 ANATOMY OF THE SKIN 
Human skin can be divided into three primary layers: the most internal layer is the 
hypodermis, the middle layer is the dermis, and the external layer is referred to as the 
epidermis (Figure 1.1).  
1.1.1.1 HYPODERMIS 
The hypodermis, also referred to as subcutaneous tissue, is the innermost layer of 
the skin below the dermis and above skeletal muscle. It is primarily composed of 
adipocytes, collagen, and blood vessels which together function as thermal insulation, 
energy storage, and protection from mechanical trauma5,6. The thickness of this layer is 
highly variable across individuals and its specific location. 
1.1.1.2 DERMIS 
The dermal layer of the skin is localized between the hypodermis and the epidermis, 
ranges between 0.3mm (eyelids) and 3mm (back) thick and is primarily composed of 
connective tissue. This layer is divided into two regions known as the papillary dermis and 
the reticular dermis. The aptly named papillary layer contains dermal papilla, localized just 
below the epidermis, which provide resistance to shear stress. The remaining reticular layer 
accounts for most of the dermis and provides structural and elastic support. Other structures 
found within the dermis include sweat glands, hair follicles, sensory receptors such as 
Meissner’s and Pacinian corpuscles, free nerve endings, and sebaceous glands (Figure 1.1). 
The primary cell types found within the dermis include fibroblasts, mast cells 
(specialized secretory cells), macrophages (phagocytic cells), and various T cells (immune 
cells)7. Fibroblasts (the major cell type of the dermis) are responsible for the synthesis of 
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the dermal matrix which consists of approximately 70% collagen with some elastin, as well 
as a mucopolysaccharide gel which fills the inter-fibrous spaces and functions as a hydrogel 
to facilitate diffusion of fluids, nutrients, and other essential components. The highly 
diverse fibroblast populations within the dermis also produce several growth factors (e.g. 
keratinocyte growth factor (KGF), hepatic growth factor) as well as many cytokines (e.g. 
interleukins (IL)-1α/β, IL-8). 
The dermis is highly innervated, which allows for its role in pain, itching, and tactile 
sensations. A critical function of the dermis is to support the epidermis by providing 
essential nutrients. Due to the lack of blood supply to the epidermis, the richly vascularized 
dermis provides a supply of nutrients and oxygen to the epidermis via diffusion1,5,6,8. 
1.1.1.3 EPIDERMIS 
The exterior layer of the skin is the epidermis [epi- (on top of, Ancient Greek) the 
dermis] which functions as our foremost barrier between internal tissues and the 
environment. The epidermis is composed of a stratified squamous epithelium composed of 
several distinct layers. Thick skin (found on palmar and plantar surfaces) has an epidermal 
thickness of 0.8-1.5mm, while thin skin (majority of our skin) has an epidermal thickness 
ranging from 0.07-0.15mm1. 
The primary cell type found in the epidermis are keratinocytes (constituting >90% 
of the epidermal cell population1) which undergo carefully controlled differentiation to 
form the stratified epithelium of the epidermis. The four layers of the epidermis from the 
most internal to the most external are; the stratum basale (SB, basal layer), stratum 
spinosum (SS, spinous layer), stratum granulosum (SG, granular layer), and the stratum 
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corneum (SC, corneal layer) (Figure 1.2). Melanocyte cells, also found within the 
epidermis, are responsible for production of melanosomes, which contain the dark pigment 
melanin. Melanin provides essential protection from UV radiation by absorbing harmful 
high energy photons and preventing them from causing permanent damage to cellular 
DNA. Langerhans cells are antigen-presenting cells, originating from monocytes, which 
provide immunologic defense within the skin1,5,6,8. 
1.1.1.3.1 EPIDERMAL STRATIFICATION 
Stratification and maintenance of the epidermis is the result of a careful regulation 
of keratinocyte differentiation and proliferation. Proliferating keratinocytes originate from 
Figure 1.2: The human epidermis. Human skin section (left) showing dermal 
collagen (yellow) and epidermal keratinocytes (pink/purple), merged with an 
illustration of the epidermis (right). The four distinct layers of the epidermis 
(basal, spinous, granular, and corneal) can be seen in both images.  
Adapted from: left, Frankart et al. (2012); right, Graham-Brown et al. (2016), 





keratinocyte stem cells found in the basal layer of the epidermis. As these keratinocytes 
undergo the process of terminal differentiation, they migrate upwards to sequentially form 
the suprabasal layers. Each of these layers have unique, critical characteristics and 
morphologies (Figure 1.3). In vivo, the differentiation process from basal to corneal 
keratinocytes is estimated to take approximately 14 days, where they remain for about 
another 14 days as corneocytes before subsequent desquamation (shedding of the 
outermost layer). The total skin rejuvenation cycle takes around 28 days5,6,8,9. 
1.1.1.3.2 STRATUM BASALE 
The basal layer, also called the stratum basale, is the innermost layer of the 
epidermis found directly above the dermis. This layer is composed of 1-3 layers of 
undifferentiated, cuboidal keratinocytes which can either replenish basal cell populations, 
or undergo terminal differentiation. Melanocytes, which produce the UV-absorbing 
melanosomes, are also found within this layer and account for 5-10% of basal cells. 
[Ca2+] pH Figure 1.3: Epidermal keratinocyte 
differentiation. Each layer of the epidermis has 
unique properties and expression patterns related 
to the state of keratinocyte differentiation (left). 
Relative calcium and pH gradients in each layer, 
which play an important role in differentiation 
and desquamation, respectively (right). 
Adapted from: Eckhart et al. (2013), with 




Basal stem cell populations are responsible for maintaining epidermal homeostasis. 
Several hypothesis on the mechanisms of this are available, however, the currently favored 
of them suggests a combination of symmetric and asymmetric cell division10–13. This 
hypothesis states that stem cells can either self-renew (symmetric), differentiate 
(symmetric), or asymmetrically divide, to maintain stem cell populations while generating 
differentiating keratinocytes for the suprabasal layers (Figure 1.4). 
The extracellular matrix (ECM) interface separating the basal epidermis from the 
underlying dermis is known as the basement membrane zone. Polarized basal keratinocytes 
produce intracellular intermediate filaments (keratins 5 and 14), which provide an anchor 
for integrin complexes (hemidesmosomes). These hemidesmosomes provide the necessary 
attachment to the laminin- and collagen-containing basement membrane5,13,14. Proper 
Figure 1.4: Cell division of basal keratinocytes. Representation of 
symmetric and asymmetric cell division thought to be the mechanisms 
responsible for epidermal maintenance by basal keratinocytes. 
Adapted from: Simpson at al. (2011), with permission from Springer Nature
(lic. #: 4606630776515) 
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attachment at the dermal-epidermal junction is mechanistically complex, but essential to 
the skin’s ability to provide a functional barrier. 
1.1.1.3.3 STRATUM SPINOSUM 
Just above the stratum basale lies the 8-10 cell deep1 stratum spinosum (spinal 
layer) of the epidermis. Once basal keratinocytes have been committed to terminal 
differentiation, they lose their columnar appearance and become increasingly polygonal as 
they form the spinal layer. 
In addition to keratinocytes, 2-8% of the cells within the spinous layer are dendritic 
Langerhans cells1. Langerhans cells are monocyte-derived, antigen-presenting cells 
originating from bone marrow, which play a critical role in the immunologic functions of 
the skin. Once an antigen has been captured, Langerhans cells may migrate to the peripheral 
lymph nodes to present it to the appropriate T cell, or activate resident T cells within the 
epidermis15, to initialize the required immunologic response16. 
The name of this layer originates from the appearance of spinous keratinocytes 
when stained with hematoxylin and eosin (HE) dyes and viewed under a microscope. The 
staining process causes the cells to shrink, while the cadherin-based desmosomes keep the 
cells bound to each other, resulting in “spines” forming at each interface. Desmosomes, 
tethered by intracellular keratin filaments, are intercellular connections between 
keratinocytes forming strong, shear-resistant bonds within the tissue. 
As keratinocytes integrate into the spinous layer, genes for the fibrous protein 
keratins (KRT) found in proliferating basal keratinocytes (KRT5 and KRT14) are turned 
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off, and expression of KRT1 and KRT10 takes over. For this reason, KRT1 and KRT10 
gene expression is often used as a marker of keratinocyte differentiation13,14. 
1.1.1.3.4 STRATUM GRANULOSUM 
The next stage of differentiation forms the 3-5 cell thick granular layer, named after 
the dark-staining keratohyalin granules (KG) found within the keratinocytes of this layer. 
Keratohyalin granules contain pro-filaggrin which undergoes proteolysis to become to the 
keratin-aggregating protein filaggrin (FLG). These aggregated keratins make up a flexible 
matrix which also contains involucrin (IVL) and loricrin (LOR). IVL and LOR are 
structural proteins which play an important role in the cornification process needed to 
create to the stratum corneum5,9,17. 
The stratum granulosum is the primary location of epidermal tight junctions (TJ, 
can also be found in hair follicles18) which are critical barrier components responsible for 
controlling paracellular fluid and ion diffusion, and protecting against pathogen 
penetration. Tight junctions are composed of intercellular claudins (CLDN), occludin 
(OCLN), and junctional adhesion molecules (JAM), scaffolded to intracellular zonula 
occludens (ZO) proteins linked to the cell’s actin cytoskeleton (Figure 1.5)13,19–21. 
The careful regulation of calcium ions in the epidermis plays a major role in 
regulating keratinocyte differentiation. A calcium gradient, with the highest concentrations 
found in the stratum granulosum and concentrations decreasing both above and below, is 
tightly controlled to maintain proper function22 (Figure 1.3). Elevated calcium levels 
activates enzymes in the protein kinase C (PKC) family which will downregulate KRT1 
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and KRT10, while upregulating IVL, LOR, and transglutaminases (TGM)23 expression, 
which in addition to FLG, are used as markers of late keratinocyte differentiation. 
Morphologically, granular keratinocytes undergo a characteristic flattening and 
observable degradation of their nuclei and organelles. Lipid- and hydrolase-secreting 
lamellar bodies being to form and produce an extracellular “mortar” at the granular-
cornified transition24. The drastic changes seen in the granular layer prepare the 
keratinocytes for their final transition into the stratum corneum by a process known as 
cornification. 
1.1.1.3.5 CORNIFICATION AND THE STRATUM CORNEUM 
The outermost layer of skin, and terminal destination for keratinocytes, is the 
stratum corneum, also referred to as the corneal layer. In a process that began in the 
granular layer, keratinocytes undergo a distinct type of programmed cell death called 
cornification. The nucleus and other organelles (i.e. mitochondria, Golgi apparatus, 
Figure 1.5: Structure of tight junctions found in the stratum granulosum. Tight 
junctions play an important role in skin barrier function by preventing paracellular 
diffusion through the granular layer of the epidermis. 




ribosomes, endoplasmic reticulum) are degraded and replaced by structural proteins and 
other corneal layer components.  
FLG, formed within the granular keratinocytes, aggregate keratin filaments which 
causes the keratinocytes to collapse into organized sheets of flattened polyhedral cells 
named corneocytes. Proteins such as IVL, LOR, trichohyalin (TCHH), and small proline-
rich proteins (SPR) are expressed and cross-linked by TGMs to form a cornified envelope 
(CE) on the cytoplasmic side of the cell membrane. The CE of each corneocyte is linked 
to neighboring CEs via modified desmosomes, referred to as corneodesmosomes, to form 
tight bonds within the stratum corneum. Lamellar bodies secrete their lipid- and enzyme-
rich contents (e.g. ceramides, sterols, phospholipids) which function as a “mortar” between 
the layers of protein-rich corneocyte “bricks” (Figure 1.6)9,17,25. 
Figure 1.6: Lamellar body secretion during the formation of the 
stratum corneum. Lamellar bodies originating in the stratum granulosum 
release lipids and enzymes, which play critical roles in barrier function, into 
the stratum corneum where they act as an inter-corneocyte “mortar”. 
Adapted from: Proksch et al. (2008), with permission from John Wiley and 
Sons (lic. #: 4606641010025) 
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The stratum corneum is highly variable in thickness depending on location and can 
be anywhere from 15 (upper arm) to hundreds (palms and soles) of layers thick1. 
Considering the thick and tightly bound, hydrophobic makeup of the corneal layer, it is no 
surprise that it also plays a major role in skin barrier function.  
As epidermal tissue is constantly being rejuvenated, a mechanism to make way for 
new tissue is necessary. The process of desquamation refers to the controlled shedding of 
corneocytes from the outermost layers of the stratum corneum. As corneocytes migrate 
from the deeper, denser corneal layers (stratum compactum) to the upper corneal layers 
(stratum disjunctum), they undergo compositional changes which promote desquamation6.  
One such change is a shift in the equilibrium of proteases and protease inhibitors, which 
allows for proteolysis of corneodesmosomes and shedding of those corneocytes. This 
balance is thought to be controlled by the pH gradient found in the corneal layer. The 
stratum compactum maintains a fairly neutral pH, ideal for protease and inhibitor function, 
however, the stratum disjunctum is markedly more acidic (pH 4-6)26,27, which reduces 
protease inhibitor effectiveness28. (Figure 1.3) Although protease function is also decreased 
by the low pH, they are less effected than protease inhibitors, so the resulting desquamation 
is gradual and well controlled. 
1.1.1.4 SKIN BARRIER FUNCTION 
As previously discussed, the major function of the epidermis is maintaining a 
proper barrier between internal tissues and the external environment. The barrier can be 
divided into two major categories; the inside-outside barrier, consisting of fluid, ion, and 
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thermal homeostatic mechanisms, and the outside-inside barrier, protecting internal tissues 
from pathogens, allergens, UV radiation, mechanical, and chemical insults. 
As the outermost layer, the stratum corneum is the skin barrier’s first line-of-
defense. The tightly bound layers of corneocytes and extracellular lipids provide a 
hydrophobic and difficult to penetrate barrier which contributes to both inside-outside 
(fluid regulation), and outside-inside (penetration) protections. The SC also contains 
antimicrobial peptides (AMPs), cytokines, antioxidants, and many other components that 
provide additional protections essential to the barrier function (see Section 1.1.1.3.5). 
In addition to regulating desquamation, the previously mentioned acidic 
environment of the skin surface aids in processing barrier lipids and discourages 
pathogenic bacteria proliferation in favor of the normal skin flora26. 
Tight junctions found on the apical side of keratinocytes in the stratum granulosum 
are another significant component of the epidermal barrier. These cell-cell junctions tightly 
bind keratinocytes together forming a paracellular barrier not only to xenobiotics and 
pathogens, but also passively regulating bi-directional fluid and ion permeability29 (see 
Section 1.1.1.3.4). 
The pathogen-directed skin barrier components are the first line of defense 
protecting our internal tissues from infection. The presence of a healthy skin microflora 
has recently gotten more recognition as an important exogenous component of the skin 
barrier. By outcompeting pathogenic microbes on the surface of the skin our microflora 
decreases our risk of infection30. Keratinocytes also produce antimicrobial peptides 
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(AMPs, e.g. β-defensins and cathelicidins), delivered from lamellar bodies, which protect 
against bacteria, viruses, parasites, and fungi31. Finally, if an antigen gets past these initial 
protections, whether through barrier deficiency or physical injury, it is the role of spinous, 
antigen-presenting Langerhans cells to activate an immunological response (see Section 
1.1.1.3.3). 
Epidermal cytokines released by keratinocytes also play a role in maintaining the 
skin barrier by activating signaling cascades in response to insults. Cytokines such as IL-
1α/β, tumor necrosis factor (TNF)α, IL-17α, IL-34, IL-24, and others, will activate the 
repair process of damaged tissue and induce a pro-inflammatory signal30,32,33. 
The interaction between individual components contributing to the homeostatic 
mechanisms which maintain the barrier are important to consider as well. Studies have 
found that the corneal barrier and granular tight junctions will compensate for decreased 
function of the other (e.g. increase in TJs when corneum is disrupted34 or a denser, thicker 
corneum in claudin-1 deficient mice35). Studies have also found interactions between the 
immune barrier and the corneal and granular barriers being able to compensate for, or 
activate, when the other is deficient32,36–38. 
1.1.1.4.1 MEASURES OF EPIDERMAL BARRIER FUNCTION 
There exist several established methods to assess epidermal barrier function, both 
in vitro and in vivo, which allow researchers and physicians to quantify changes in barrier 
function. 
Transepithelial electrical resistance (TEER) is a common, non-destructive 
methodology used to measure barrier function in vitro. It functions by placing an electrode 
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above and below a tissue immersed in culture media (Figure 1.7) acting as an electrolyte, 
and applying a weak alternating current (10µA) which allows for a measure of electrical 
resistance (ohm, Ω) across the tissue. By subtracting out the resistance of an empty cell 
culture insert, the specific resistance of the tissue itself can be determined. This resistance 
is directly related to the freedom of ion to flow through the tissue via paracellular 
(controlled by tight junctions) and transcellular pathways. A decrease in TEER corresponds 
to decreased resistance to ion permeability across the tissue, and therefore a weaker 
epithelial barrier. 
Trans-epidermal water loss (TEWL) is another non-invasive measure of barrier 
integrity which, unlike TEER, can be used both in vivo39 and in vitro40. As implied, TEWL 
is a measure of the passive diffusion of water across the epidermis, which is directly related 
the skin’s inside-outside barrier function. The TEWL instrument used in these studies 
(Biox Aquaflux AF200) utilizes a sealed condenser chamber, which is placed over the 
tissue in an airtight manner (Figure 1.8). The chamber contains a chilled (-7.65°C) 
condenser plate to control the humidity within the chamber, as well as relative humidity 
Figure 1.7: Illustration of TEER 
electrode placed in measurement 
position. Using electrode placed on 
either side of a tissue submerged in 
culture media, we can determine the 
electrical resistance across the tissue 
as measure of tissue barrier integrity.
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and temperature sensors between the condenser and the epidermis. As water vapor diffuses 
from the tissue surface to the condenser, the sensors calculate water vapor flux over time. 
To correct for the initial skin surface water loss (SSWL), which could contaminate the data, 
TEWL is measured over a period of 60-90s and once a steady state threshold has been 
achieved the water flux is recorded as mass of water per area over time (typically g/m2h). 
Although TEWL is a useful tool to measure barrier integrity, it is inherently sensitive to 
subtle external influences. Care must be taken to maintain constant ambient humidity and 
temperature and ensure the surface of the tissue is thoroughly dried before measurement. 
Other methods to measure barrier function include chemical permeation assays. A 
low-binding, low-molecular weight chemical can be applied to the surface of the tissue and 
the amount that is able to permeate into the media below can be quantified. Fluorescent 
dyes are commonly used for this type of assay and can also be used to visualize dye 
penetration by fluorescent microscopy of tissue cross-sections. A downside is this type of 
assay is the invasive nature of chemical treatments, which may affect the tissue in 
unpredictable ways. These assays are typically performed in independent, single-use 
Figure 1.8: Illustration of 
TEWL measurement device on 
reconstructed epidermis. An 
evaporimeter measures water flux 
through the tissue. TEWL is used 
in vivo, or in vitro (shown here), 
to assess skin barrier integrity 
based on water permeability. 
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studies, whereas TEER or TEWL can be measured multiple times at several stages of tissue 
growth, or at various treatment times, in most studies without interfering with other 
downstream assays. 
1.2 DISEASES OF THE SKIN 
Since the skin plays such a major and critical role in protecting us from the insults 
of our environment, it is no surprise that skin diseases can have a devastating effect on 
patient health and quality of life. As previously discussed, maintaining healthy skin 
involves a series of carefully regulated, complex biological process for proper function. 
Even seemingly minor perturbations of many of these processes can result in severe disease 
states requiring medical intervention. Untreated skin diseases can result in increased 
infection risk, severe irritation, allergen sensitization, dehydration, vitamin D deficiency, 
thermal dysregulation, UV-damage, and psychological distress8. 
1.2.1 CONGENITAL ICHTHYOSIS 
Congenital ichthyoses are a group of hereditary keratinization disorders. 
Keratinization is the process of keratinocyte differentiation, referring to the formation of 
keratin filaments. Originally derived from the Greek word for fish (“ichthys”), ichthyosis 
can cause skin to resemble fish scales due to improper cornification (Figure 1.12a41). 
Congenital ichthyosis covers a wide gamut of related disorders and as such, there 
are many possible genetic causes attributed to the disease (Table 1.142). Some forms, such 
as ichthyosis vulgaris and recessive x-linked ichthyosis (RXLI), are more common (1/300 
and 1/2,500 respectively), while others, such as lamellar ichthyosis (LI) and bullous 
ichthyosis, are fairly uncommon (1/100,000 and 1/300,000 respectively)43. Severity is also 
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highly variable with less severe forms, such as ichthyosis vulgaris, having low mortality, 
while other forms, such as harlequin ichthyosis, resulting in neonatal survivability as low 
as 56%44. Symptoms can include dry skin (xerosis), redness and irritation (erythema), 
scaling and blisters, abnormal thickening of the skin (hyperkeratosis), and other 
problematic conditions43. 
Current treatment options for these disorders typically target a combination of three 
strategies; hydration, lubrication, and keratolysis43. The two former strategies focus on 
mitigating symptoms, while the latter (often via retinoid treatment) targets the underlying 
biological mechanisms the diseases. Retinoid-related treatments (further discussed in 
Section 1.3) function as keratolytics and reduce hyperkeratosis, keratinocyte 
hyperproliferation, and excessive corneocyte production. Unfortunately, this treatment 
mechanism can result in adverse effects, including additional barrier dysfunction, and often 
require additional treatment with antimicrobials. 
Table 1.1: Major types of congenital 
ichthyosis by culprit gene. Ichthyosis 
can be caused by many different genetic 
components. A disruption in any of the 
critical factors involved in the complex 
process of keratinization can result in 
dysfunction and medical complications.  
Source: Online Mendelian Inheritance 
in Man (OMIM, https://omim.org). 
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1.2.2 DARIER’S DISEASE 
Darier’s disease (DD, keratosis follicularis) is a rare (between 1 in 36,000 and 1 in 
100,00045), autosomal dominant skin disorder characterized by disrupted intercellular 
adhesion (acantholysis) and abnormal keratinization (dyskeratosis). DD is caused by a 
mutation in the ATP2A2 gene which encodes a calcium transporter (SERCA2)46 found in 
the endoplasmic reticulum of keratinocytes. Due to the importance of calcium ion gradients 
in skin development, epidermal homeostasis is consequently disrupted in DD. This results 
in abnormal keratinocyte differentiation, poor intercellular adhesion, and dark, crusty skin 
lesions, which together cause severe itching, pain, and increased risk of infection. 
DD is treated similarly to other keratinization disorders; emollients and 
corticosteroids to address irritation, retinoids to control dyskeratosis47–49, and antibiotics 
which may be used during flare ups. Retinoids such as isotretinoin (13-cis-retinoic acid), 
adapalene, tazarotene, acitretin, and others, have been used in the treatment of DD via 
topical and oral formulations45,47,49,50.  
1.2.3 ATOPIC DERMATITIS 
Atopic dermatitis (AD) is a common chronic inflammatory skin disease (affects 15-
30% of children and 2-10% of adults) with recently increasing prevalence51. AD patients 
present with xerosis, itching (pruritus), lesions of erythema which increase the risk of 
infection, and atopy (a genetic tendency to develop allergen sensitization)52. Since there 
are no specific markers for AD, diagnosis can be difficult and is typically done by looking 




Noted features of AD are barrier dysfunction, measured by increased TEWL, 
inflammation, and immune dysfunction. It is currently unknown if one may lead to the 
other, but it is clear they are closely linked to each other and both genetic and 
environmental factors contribute to AD54,55. Mutations in barrier proteins, such as FLG and 
SPINK5, as well as immune factors such as IL- 4 & 13, toll-like receptor 2 (TLR2) and 
others have been associated with AD56,57. 
Like congenital ichthyosis, current AD treatment options are limited and often 
target symptoms rather than the underlying causes. Moisturizers and emollients hydrate the 
skin and mitigate TEWL, cortical steroids and calcineurin inhibitors target inflammation, 
and in severe cases, immunosuppressants are also used. Finally, ceramide and lipid-based 
formulations can be used to partially restore some barrier function lost in AD. 
1.2.4 OTHER SKIN DISEASES 
There exists such a wide gamut of different skin diseases that discussing the field 
of dermatology in its entirety is not feasible in this summary. This section will provide a 
very brief description of a few other skin disorders, primarily focusing on those that 
respond to retinoid-related treatments. 
Psoriasis is a common (3% of western population8) inflammatory autoimmune skin 
disease. Interactions between keratinocytes, T cells, cytokines and chemokines all 
contribute to psoriasis. Psoriatic epidermis displays keratinocyte hyperproliferation, 
specifically increased stratum basale and stratum spinosum thickness (acanthosis), and 
inflammatory cell accumulation. There are several subtypes (plaque, guttate, inverse, 
pustular, erythrodermic, and others) and their symptoms include skin redness/irritation, 
20 
 
itching (pruritus), lesions, pain, and increased risk of infection.  Treatments for psoriasis 
vary but often include combinations of steroids, vitamin D, phototherapy (UV exposure), 
immunosuppressants,  emollients, retinoids, and most recently, various biologics8,58,59. 
Acne vulgaris is a skin condition that nearly everyone has had some direct 
experience with, particularly during adolescence (~90% of teenagers have acne60). Acne is 
caused by the blockage of sebaceous glands resulting in inflammation and lesions 
(blackheads, whiteheads, pimples, etc.). Processes that contribute to this include abnormal 
keratinocyte proliferation/desquamation, overproduction of sebum, bacterial infection 
(Propionibacterium Acnes), and inflammation60. Acne, like most externally presenting skin 
diseases, not only causes physical detriments, but also has a significant mental health 
component which can cause great suffering for affected patients. Treatments include 
retinoids, antibiotics, hormone therapies, and cleansing agents (salicylic acid, benzoyl 
peroxide) aimed at desquamation, clearing blockages, and/or reducing bacterial infection60.
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1.3 RETINOIDS AND RELATED COMPOUNDS 
The term retinoid refers to the class of compounds chemically related to vitamin A. 
Vitamin A specifically refers to retinol (ROL), while retinoids include the entire family of 
bioactive metabolites and precursors of ROL including, but not limited to, retinal (RAL), 
retinoic acid (RA), and the various synthetic analogs acting on endogenous retinoid 
pathways (Figure 1.9). Due to the pleiotropic nature of retinoid biopathways, and their 
essential and diverse cellular functions, retinoids are ubiquitously required in all stages of 
human development. Vitamin A and its active metabolites play an essential role in many 
biological processes including, but not limited to; vision, immunity, reproduction, 
metabolism, neurologic function, development, and cellular differentiation61. 
1.3.1 RETINOID TARGETS AND MECHANISMS 
Endogenous retinoids display a complex and essential role in many biological 
processes and many of these roles still consist of incompletely defined mechanisms. A 
review of 1,191 publications found over 532 genes that appear to be regulated by RA62. 
Figure 1.9: Common retinoids in the vitamin A family. 
Also showing the dietary retinal precursor, β-carotene. 
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This vast breadth of regulatory effects RA exerts on gene expression illustrates how 
extensively retinoids contribute to our biology. 
The primary targets of retinoids are nuclear receptors (NRs) including retinoic acid 
receptors (RARs) and retinoid X receptors (RXRs) which, when activated, regulate gene 
transcription. RARs consist of three subtypes, each with multiple isoforms (α1/2, 
β1/2/3/4/1’, and γ1/2), and can be activated by either all-trans retinoic acid (atRA) or 9-
cis-RA. RXRs also consist of three subtypes, each with multiple isoforms (α1/2, β1/2, and 
γ1/2), but are only known to be activated by the 9-cis form of RA (whether or not 9-cis RA 
is the bona fide ligand is still up for debate)63. RARs form heterodimers with RXRs, which 
will bind to specific DNA sequences called RA response elements (RAREs) found in the 
regulatory regions of their target genes. RXRs can form a very diverse range of active 
dimers as either homodimers or heterodimers with other NRs such as thyroid receptor (TR), 
liver X receptor (LXR), peroxisome-proliferator-activated receptors (PPARs), vitamin D 
receptor (VDR), and many others63 (Figure 1.10). 
Recent discoveries have also revealed that RA can bind other NRs such as 
PPARβ/δ, while other studies have found evidence of antagonistic interactions via RAR-
related orphan receptor β (RORβ) and other NRs61. Further complicating the genomic 
effects of RA is the deep involvement of coregulators (coactivators and corepressors), 
which interact with RA-interacting NRs, and the variable sequences and geometries of 
RAREs contributing to gene regulation63. RARs also display protein-protein interactions 
with activator protein-1 (AP-1), a transcription factor regulating expression of cytokines, 
23 
 
growth factors, metalloproteases, and many other targets. The RAR/RXR/AP-1 complex 
acts to repress the expression of both RAR and AP-1 regulated genes64 (Figure 1.10). 
In addition to the genomic effects discussed above, retinoids also display non-
genomic effects, an area of study which still requires significant research to properly define 
and comprehend. Studies have shown that RA can activate several kinase cascades 
including some mitogen-activated protein kinases (MAPKs) and extracellular signal-
regulated kinases (Erk)65. ROL has also be found to activate Janus kinases/signal 
transducer and activator of transcription 5 (JAK/STAT5)61. RA can also affect post-
translational protein modifications in a process called retinoylation66 (Figure 1.10). 
Figure 1.10: Illustration of some targets and biopathways of endogenous 
retinoids. Both genomic and non-genomic effects, many of which remain poorly 
understood, play a role in the biological effects of retinoids. 
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1.3.1.1 RETINOIDS IN THE SKIN 
Retinoids are found ubiquitously, and play many critical roles, in our bodies. Within 
the skin, the roles of retinoids include regulation of keratinocyte proliferation, 
differentiation, apoptosis, and maintaining barrier and immune functions67. Endogenous 
levels of retinoids can vary greatly from one individual to another; approximate 
concentrations in healthy humans are ~2-4nM atRA and ~800nM ROL in the skin68, 4-
14nM atRA and 1-2µM ROL in serum69. 
RARγ and RARα are both found in the skin, although the levels of RARα are much 
lower. RXRs are more abundant than RARs with RXRα being the most common subtype 
in the skin. Unsurprisingly, the most commonly found RAR/RXR dimer pair within the 
skin appears to be the RARγ-RXRα complex70. 
Many cytokeratins (KRT5/6/14/17)71, the RA-transporting protein CRABP-II72, the 
RA-metabolizing enzyme cytochrome P450 (CYP)26A173, and many other genes 
expressed in the skin, contain RAREs within their promotor regions. There are many other 
genes, including heparin-binding EGF-like growth factor (HBEGF), KRT1/2/4/10, 
CYP26B1, and others, which are not known to contain RARE promotors, but are clearly 
regulated by retinoids. A study investigating the effects of retinoids on the expression of 
475 skin-related genes in reconstructed human epidermis found 44 genes were variably 
expressed74. In addition to the genomic effects of retinoids, non-genomic targets such as 
AP-1 (antagonized by RA and RARs) play an important role in epidermal differentiation75. 
The role of retinoids in skin barrier function include regulating epidermal 
permeability, keratinocyte differentiation76, sebum production77, and apoptosis78. Studies 
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have found that disrupting retinoid-related receptors in the skin results in epidermal 
dysregulation79,80. Transgenic mice with complete loss of function of the RA-metabolizing 
enzyme CYP26B1, leading to abnormally high RA levels, show decreased expression of 
barrier proteins and barrier dysfunction81. Inhibition of retinoid signaling has also been 
shown to cause disruption of the lipid barrier82. These studies, and many others showing 
both increased and decreased retinoid signaling will disrupt barrier formation, together 
illustrate a so-called “goldilocks” zone of retinoid signaling in the skin. 
Retinoids also play an important role in maintaining epidermal immune functions 
(previously discussed in Section 1.1.1.3) which contribute to the skin’s role in regulating 
pathogen/allergen exposure and mediating inflammation. RAR and RXR pathways are also 
involved in T helper cell development83–85 and retinoids are known to regulate cytokine 
and chemokine levels86,87. 
Due to the robust effects of retinoids in many skin functions, they are commonly 
used in the treatment of many skin diseases (see Section 1.2). Keratinization and epidermal 
proliferation disorders such as congenital ichthyosis41,49,88, psoriasis89–91, Darier’s 
disease47,48, and many others respond to retinoid treatment and continue to be studied 
within this context. Retinoids such as tretinoin, adapalene, and tazarotene are also used in 
the treatment of mild- to severe- acne58. Retinoids have also shown promise in treating 
inflammatory skin diseases such as atopic dermatitis68. Their ability to control cellular 
differentiation and apoptosis have also led researchers to study retinoids for the prophylaxis 
or treatment of skin cancers58.  
26 
 
1.3.2 BIOSYNTHESIS, TRANSPORT & METABOLISM OF 
ENDOGENOUS RETINOIDS 
Retinol (ROL) is primarily obtained via its dietary precursors: animal-origin retinyl 
esters (RE) and plant-origin carotenoids like β-carotene. Ingested dietary REs are 
hydrolyzed to ROL in the intestines, absorbed, and complexed with cellular retinol binding 
protein (CRBP)-II. Carotenoids are absorbed in the intestines, oxidized into retinal (RAL, 
which can complex with CRBP-II as protection from oxidation), and reduced to ROL via 
a retinal reductase. The ROL-CRBP-II complex can then interact with lecithin:retinol 
acetyltransferase (LRAT) which catalyzes esterification of ROL to RE. RE is then 
transported by chylomicron to the liver for long-term storage (50-80% of all the vitamin A 
in the body is stored as RE). ROL is transported in the blood by the plasma transport protein 
retinol binding protein (RBP), and delivered to its target cells61,67 (Figure 1.1166). 
Following uptake into keratinocytes, which is likely mediated by a cell surface RBP 
receptor, ROL binds CRBP-I which assists in stabilization and transport92. ROL will then 
either be metabolized to RE by LRAT or acyl-CoA:retinol acyltransferase (ARAT)93, or 
reversibly converted to RAL by alcohol dehydrogenases (ADH) and short-chain 
dehydrogenases/reductases (SDR). RAL can then be irreversibly converted to retinoic acid 
(RA) by an aldehyde dehydrogenase (ALDH), namely, retinal dehydrogenase (RalDH)94. 
RA will then bind cellular retinoic acid binding protein (CRABP) I or II, which can 
facilitate either RA degradation or nuclear transport. CRABP has the highest affinity for 
atRA, with low and no affinity for 9-cis-RA and 13-cis-RA, respectively95. 
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RA metabolism is catalyzed by heme-containing cytochrome P450 enzymes 
(CYPs), a superfamily of 57 [in humans] enzymes responsible for the metabolism of many 
endogenous and exogenous compounds, as well as an estimated 75% of marketed 
pharmaceuticals drugs96. The CYP26 family is the primary enzyme responsible for 
metabolism of RA, however, other non-RA-specific CYPs have also been reported to 
metabolize RA97. CYP26 enzymes (three human isoforms: CYP26A1, CYP26B1, 
Figure 1.11: Absorption, transport, and processing of retinoids. Retinyl 
esters and β-carotenes found in our diet are intestinally absorbed, converted 
to retinol in the liver, then distributed to its target cells where it is converted 
to retinoic acid and exhibits its biological effects. CYP26 enzymes are 
responsible for the metabolism of retinoic acid. TTR, transthyretine; RBP, 
retinol binding protein; CRBP, cellular retinol binding protein; RDH, 
retinol dehydrogenase; RALDH, retinaldehyde dehydrogenase; RAR, 
retinoic acid receptor; RXR, retinoid X receptor.  




CYP26C1) are unique due to their selectivity for RA metabolism. CYP26 research has 
primarily focused on the CYP26A1 and CYP26B1 isoforms in part due to the low levels 
of CYP26C1 expression seen in adult human tissues98. In vitro and in vivo studies have 
shown autoinduction of CYP26A1 expression by RA99–101, a mechanism generally 
accepted to be controlled by RAR/RXRs bindings to RAREs found in the promotor region 
of many RA-regulated genes102,103. CYP26B1 gene expression is also induced by RA, 
however, only CYP26A1’s promotor has been found to contain a RARE73. Tissue 
distribution of each isoform varies (e.g. CYP26A1 is the primary hepatic isoform97, 
CYP26B1 the primary brain isoform98), however, both can be found in skin tissue. Studies 
have found that CYP26A1 expression tends to be restricted to basal epidermal 
keratinocytes104, while CYP26B1 has greater expression in the dermis and hair follicles 
than the epidermis81. 
1.4 RETINOIC ACID METABOLISM BLOCKING AGENTS 
Retinoid therapies (available in oral and topical formulations) have successfully 
been used in the treatment of a variety of skin diseases (detailed in Section 1.2). These 
include endogenous retinoids like all-trans RA (tretinoin) and 13-cis RA (isotretinoin), and 
synthetics including tazarotene, adapalene, and many others. Although retinoids are 
commonly used in clinical settings, the adverse effects of these drugs (e.g. skin irritation, 
dryness, photosensitivity, hyperlipidemia, hyperostosis, teratogenicity, and more)58 can 
result in complications or noncompliance in many patients. 
To address adverse effects and the issue of tolerance (resulting from autoinduction 
of its metabolism) by direct retinoid therapy, a new class of drugs called retinoic acid 
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metabolism blocking agents (RAMBAs) were developed. These act by blocking RA 
metabolism via selective inhibition of CYP26-mediated RA metabolism105. 
The antifungal agent ketoconazole was the first studied after it was found to inhibit 
CYP-mediated RA metabolism, however, its use was short lived due to off-target 
activity106. The first-generation of CYP26-specific RAMBAs such as liarozole (Figure 
1.13), successfully inhibited the metabolism of RA107 and showed great promise in treating 
several skin disorders41,88,90,91,108,109 including psoriasis and ichthyosis (Figure 1.1241). 
Liarozole, although extensively studied and progressing to late-stage clinical trials, 
displayed non-specific effects including interference of hormone biosynthesis106, which 
may be the reason they have not progressed to clinical use in the US. The more selective 
Figure 1.12: Non-erythrodermic lamellar ichthyosis patient treated with 5% 
topical liarozole showing marked improvement. (a) before treatment, (b) 
patient's left side treated with liarozole & patient’s right side treated with vehicle 
only, (c) liarozole treatment on both sides. 




and potent RAMBA, talarozole (R115866) (Figure 1.13), was synthesized to address the 
issues seen with liarozole110. Talarozole has also been shown to alter the expression of 
retinoid-related genes111 and underwent several successful topical and oral clinical trials 
for the treatment of acne and psoriasis89,112, however, development was halted in 2008, 
likely for budgetary reasons113.  
In response to this gap in the development of CYP26-inhibitors, Diaz et al., have 
synthesized and screened a library of compounds with varying selectivity for the different 
CYP26 isoforms114,115 (Figure 1.13). The previous generation RAMBAs contain an azole 
moiety, which can interact with the heme found in all CYPs, is thought to contribute to 
their lack of specificity. The compounds developed by Diaz et al. aim to increase CYP26 
specificity with a series of compounds lacking this azole moiety, then, by studying 
Figure 1.13: Structures of several RAMBAs. First-generation (top) and 
two of the novel candidate compounds developed by Diaz et al. (bottom).
These next-generation RAMBAs lack the azole moiety found on the 
previous generations, which should reduce their off-target activity. 
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candidates with varying the isoform specificity, elucidate the advantages each. Initial 
screening of several early development compounds showed high CYP26 specificity and 
potency, with little detectable direct activation of RAR114. 
1.4.1 CYP26B1-SELECTIVE RAMBA: DX314 
 DX314 (previously referred to as NMP314) is a novel CYP26B1-selective 
RAMBA previously described and patented116 by Diaz et al. In these studies, we focus 
primarily on DX314 (Figure 1.13), a CYP26B1-selective compound with a 16-fold higher 
selectivity for CYP26B1 over CYP26A1, and no detected inhibition of CYP19 (estrogen 
synthase), in contrast to liarozole and talarozole (Table 1.2114,116,117). DX314’s cytotoxicity 
was previously assessed (data not shown) in human keratinocyte, dermal papilla cell, and 
SH-SY5Y monolayer cultures, which found no evidence of significantly decreased cell 




Table 1.2: Previous and novel RAMBA cytochrome P-450 IC50 values. CYP26A1 
and CYP26B1 were expressed in SF9 cells and prepared as microsomal fractions. 
100nM 9-cis-RA was used as the substrate and formation of the metabolite 9-cis-OH-












𝟏 𝟏𝟎(𝑰 𝐥𝐨𝐠 𝑰𝑪𝟓𝟎)
. CYP2C8, CYP3A4, and CYP19 inhibition 
assays were performed in pooled human liver microsomes using paclitaxel (4µM), 
midazolam (0.5µM), and estrone (1µM), as the respective substrates. Product 
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2. DX314 POTENTIATES THE EFFECTS OF RA, WHILE 
PROTECTING BARRIER FUNCTION IN 
RECONSTRUCTED EPIDERMIS 
2.1 INTRODUCTION 
During initial studies, a library of several of candidate compounds having 
previously undergone in silico and in vitro CYP26-inhibition assays, were investigated for 
cytotoxicity and retinoid-responsive gene expression changes within simple monolayer 
keratinocyte cultures. Two compounds; DX308, and this study’s focus DX314, were 
selected for further study. Here we focus on the characterization of DX314, which became 
our primary focus as it displayed the least evidence of non-specific biological effects. 
The aim of these studies is to investigate whether DX314 can potentiate the effects 
of endogenous levels of atRA, and consequently mimic the desired biological effects seen 
in retinoid-based therapies, with minimal evidence of undesirable effects. For the purpose 
of these studies, a potentiation of atRA is defined as the ability of a compound cotreated 
with low-dose atRA to display: an effect significantly different from control given said 
effect can be seen when treating with atRA alone; an effect size larger than what is seen 
with low-dose (1nM) atRA alone; and in a manner mimicking the effects seen when 
treating with higher-dose atRA alone. A RAMBA displaying little or no effect on its own 
but displaying a potentiation of atRA when they are cotreated, implies the RAMBA acts 
by inhibiting the metabolism of atRA. This would result in identical initial doses of atRA 
producing a relatively increased effect in the presence of a RAMBA. These studies were 
performed in reconstructed human epidermis (RHE) grown using primary keratinocytes 
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from healthy adult donors. Use of in vitro 3D skin models provides significant 
improvements in study relevance to in vivo conditions relative to the traditional monolayer 
keratinocyte culture. Two independent studies (Table 2.1) characterizing the effects of 
DX314 in healthy RHE are presented here. The effects of atRA, as well as the well-studied 
RAMBA liarozole, are used to compare the therapeutic potential of DX314. 
  


















Table 2.1: Outline of experiments performed 
during this study. IPA, Ingenuity Pathway 
Analysis; IHC/IF, Immunohistochemistry/ 
immunofluorescence; TEER, transepithelial 





2.2.1 PRIMARY HUMAN KERATINOCYTES 
Primary, human, adult, healthy, epidermal keratinocytes were used for all parts of 
this project. Adult, human epidermal keratinocytes (HEKa, Gibco, C-005-5C) were 
sourced from a 40yo female. NAK209 (48yo, female), NAK214 (37yo, male), and 
NAK219 (32yo, female) were generously donated to the project by our collaborator, Dr. 
Yves Poumay at the University of Namur, Belgium. 
2.2.2 CELL CULTURE 
The keratinocytes were previously isolated by the Poumay lab from skin biopsies 
as described118–120. Excess skin tissue from abdominoplasty was stored in a 4°C saline 
solution for transport to the lab. In a sterile culture hood, the tissue was placed into a petri 
dish containing solution A (10mM Glucose, 2mM KCl, 130mM NaCl, 1mM Na2HPO4, 
3.3μM phenol red, 30mM HEPES, pH 7.2-7.4, 0.22µm sterile filtered) and cut into 1-2cm2 
sections. The sections are then transferred to a petri dish containing a 4°C trypsin solution 
(0.17% w/v trypsin, 50µg/mL gentamycin, 250ng/mL fungizone, and 250ng/mL ampicillin 
in solution A) and incubated overnight at 4°C. The dermis and epidermis are then separated 
using sterile forceps and the epidermis placed in solution A containing 2% dialyzed fetal 
bovine serum (FBS) for further dissociation by manual stirring. The suspension is then 
filtered through a 70µm cell strainer, centrifuged for 10min at 160rcf and 4°C, and 
resuspended in 10mL KGM-2 bullet kit (Lonza, CC3107) supplemented with gentamycin, 
fungizone, and ampicillin in the concentrations described above. The viable cell count is 
determined with a Countess automated cell counter (Invitrogen), then 46,000 cells/cm2 are 
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plated in a 175cm2 culture flasks containing 25µL FBS and 25mL KGM-2 supplemented 
with 0.5% penicillin/streptomycin (P/S, Corning, 30002CI). This is incubated undisturbed 
for 3 days in a 37°C, 5% CO2, humidified incubator. The media is then replaced with 
Epilife Complete (Epilife media [Gibco, MEPI500CA], 1% HKGS [Gibco, S0015], 0.5% 
P/S), which is replaced every two days, and allowed to reach 50-60% confluence before 
subculturing or cryopreservation at 1e6 cells/mL in freezing media. (Epilife, 10% DMSO, 
10% FBS). 
Keratinocyte culture protocols were adapted from the protocol described by 
Poumay et al.121. Briefly, cryopreserved cells were thawed and seeded in cell culture flasks 
at 3000-12000 cells/cm2 in KGM-2 (supplemented with 0.5% penicillin/streptomycin) and 
placed in a 37°C, 5% CO2, humidified incubator for 24hrs. Media was then replaced with 
Epilife Complete, refreshed every 2 days, until ~60-70% confluence. The cells are then 
trypsinized (0.025% trypsin/0.01% EDTA), neutralized, counted, and used for RHE or 
autocrine monolayer culture. 
2.2.2.1 RECONSTRUCTED HUMAN EPIDERMIS 
The RHE protocol was adapted from the protocol described by Poumay et al.118–
120. Briefly, 2.5mL of RHE Day 0 media (Epilife Complete with 1.5mM CaCl2) is placed 
into each well of a 6-well cell culture plate. A 12mm diameter, polycarbonate membrane 
(0.4µm pore-size), cell culture insert (Millipore, PIHP01250), is then placed into each well 
using sterile tweezers. Keratinocytes (passage 3 or 4) are suspended in Epilife Complete at 
4e5 cells/mL, and 500µL of this cell suspension is pipetted into each insert (resulting in 
200k cells/insert). The plates are then placed in a 37°C, 5% CO2, humidified incubator, and 
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left undisturbed for ~24hrs. The following day, the media is aspirated and replaced with 
1.5mL RHE Day 1+ media (RHE Day 0 media with 10ng/mL human keratinocyte growth 
factor [Sigma, K1757] and 50µg/mL vitamin C), which was subsequently changed every 
two days for the remainder of the experiment. Any media remaining on the surface of each 
tissue is carefully aspirated to establish an air-tissue interface, which promotes 
differentiation and epidermal stratification. Drying of the RHE surface was done daily until 
the barrier is fully formed and media is no longer appearing on the tissue surface. RHEs 
were grown for a total of 11 days, treatments were started on day 7, refreshed day 9, and 
stopped on day 11 (Figure 2.1). All treatment groups (including controls) contained 0.1% 
DMSO as a vehicle to aid compound solubility. Preparation of any photosensitive 
compounds (i.e. retinoic acid) was performed in a dark culture hood with minimal ambient 
light. Following treatment, the RHEs were collected for RNA purification (Section 2.2.6.1) 
or histology (Section 2.2.5). 
2.2.3 TEWL 
A custom protocol was developed to allow for a minimally invasive and disruptive 
measurement of TEWL in viable RHE. This method was required to minimize physical 
Figure 2.1: Timeline of RHE growth and treatment. Media Δ, media change; 
RHE, reconstructed human epidermis; TEER, transepithelial electrical resistance; 
TEWL, trans-epidermal water loss. 
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contact with the tissue surface, allow the tissue to remain within the insert, and to not 
interfere with downstream experiments, including TEER and histology on the same tissue. 
Typical in vitro methods to quantify TEWL either required the tissue to mounted to a Franz 
cell (which requires it to be removed from the insert), or use of an evaporimeter attachment, 
which makes direct contact with the tissue surface and could potentially damage the thin 
tissue. For this reason, we constructed flexible rubber seals (using gaskets and washers 
purchased at a local hardware store and assembled with a flexible silicone-based adhesive), 
which could be sterilized in a solution of 70% ethanol. This allowed the evaporimeter to 
form an airtight seal over the insert, ensuring any measured water flux must have diffused 
through the tissue (Figure 1.8). If both TEWL and TEER were measured within a single 
experiment, TEWL was measured first, followed by a minimum of 2hrs of recovery time 
in the incubator before TEER is measured. Because TEER requires each tissue to be 
submerged in media, the residual moisture from this assay would have interfered with the 
sensitive TEWL measure. 
Plates were removed from the incubator and placed in the tissue culture hood with 
their lids slightly ajar for 15min to allow for adjustment to ambient humidity. Tissue 
surfaces were thoroughly checked for any moisture, and if needed, lightly dabbed with a 
sterile cotton swab. The plate was placed on a 37°C plate warmer to ensure consistent 
media/tissue temperature and promote diffusion and formation of water vapor at a 
physiologically relevant temperature. The custom rubber seal was fitted over the insert to 
form an airtight seal between the tissue and the AquaFlux AF200 evaporimeter (Biox) 
measurement head. TEWL was measured before (day 7) and after (day 11) treatment 
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(Figure 2.1), over 60-90s, as recommended by the manufacturer, until a steady state water 
flux was achieved. Due to the inherent sensitivity of TEWL measurements, after each tissue 
on a plate was measured once, they were sequentially measured a second time and the two 
values were combined into a single datapoint for statistical analysis. 
2.2.4 TEER 
The TEER protocol was adapted from a protocol developed by the Poumay lab, 
which was communicated by personal correspondence. Under sterile conditions, 4mL of 
Epilife media was placed into each well of a 6-well plate (a separate well for each unique 
treatment to prevent cross-contamination) and allow to come to room temperature. Use 
sterile tweezers to transfer an RHE into the media, then pipette 500µL of the underlying 
media into the insert (3.5mL of media remains in the bottom of the well). Allow the tissue 
to remain submerged for 30sec before inserting the sterile electrode (Millicell ERS-2) 
(Figure 1.7). Ideally, we would allow the TEER measure to come to a steady state before 
reading, however, we found that in many cases this could take in excess of 10min per tissue. 
We believe this is due to a slow diffusion of media into the tissue affecting the electrical 
resistance, thus causing the reading to continuously drift. For this reason, we arbitrarily 
choose a consistent 30sec measurement period for all tissues and recorded the TEER at the 
end of that period. After measurement, the media in the insert was aspirated and placed 
back into the well, the tissue surface was dried, and the RHE was placed back into its 
growth plate. TEER was measured before (day 7) and after (day 11) treatment, and 




Preparation of RHE for histological analysis is described in the RHE protocols 
above119,120. Following treatment, RHEs were immediately placed in a fixing buffer, which 
consists of 4% formaldehyde and 1% glacial acetic acid. The following day, the tissues 
were dehydrated with sequential methanol washes (1x rinse, 1x 5min wash, 2x 10min 
wash), removed from the insert, briefly rinsed in toluene, then placed in fresh toluene bath 
for 1hr at room temperature. The tissue was then rinsed in liquified paraffin and transferred 
to fresh liquified paraffin at 58°C for 1hr to allow for complete toluene-paraffin exchange. 
Finally, the tissue was perpendicularly mounted in a mold containing fresh liquified 
paraffin, covered by a histology cassette, and allowed to solidify. A microtome was used 
to take 6µm vertical sections from a depth of at least 1.5mm into the 12mm diameter RHE. 
Sections were mounted to positively charged glass slides and allowed to dry before use. 
Deparaffinization of the slides was performed in the following steps: 2x 3min 
toluene, 2x 3min methanol, 2x 3min 70% methanol, 10min circulating tap water rinse. The 
slides were then immediately used for hematoxylin-eosin (HE, Section 2.2.5.1) or 
immunohistological (Section 2.2.5.2) staining. 
2.2.5.1 HEMATOXYLIN-EOSIN STAIN 
Slides were sequentially exposed to the following baths: 3x 3min hematoxylin 
solution, 3min circulating tap water, 3min ethanol with 0.15% HCl, 10min circulating tap 
water, 2x 3min eosin solution, 3min circulating tap water, 3min 70% ethanol, 3x 3min 
isopropanol, 3min toluene. Coverslips were mounted, and the adhesive allowed to dry 




Slides were sequentially exposed to the following: PBS rinse, 2x 3min 0.1M 
glycine in dH2O, PBS rinse, then 1hr in PBS/BSA/Triton (PBS with 0.2% BSA and 0.02% 
Triton X-100). A hydrophobic marker was used to encircle the tissue and 50µL of primary 
antibody (diluted in PBS/BSA/Triton) was applied. The slides were placed in a humidity 
chamber and incubated for 1hr at room temperature. The slides were then rinsed three times 
in PBS/BSA/Triton before 1hr humidified incubation with 50µL of the respective 
secondary antibody. The slides were again rinsed three times in PBS/BSA/Triton before a 
15min incubation with 50µL of Hoechst nuclear stain (diluted in PBS/BSA/Triton) 
followed by 3x 5min PBS rinses. Coverslips were mounted with Mowiol and the slides 
were stored at 4°C until imaged on an Olympus DX63 microscope with Olympus XM10 
camera. Primary and secondary antibody sources and dilutions can be found below (Table 
2.2). 
Table 2.2: Antibodies and dyes used for immunohistological staining. 
 
Target Species Dilution Source 
IVL Mouse 1:200 Invitrogen, I9018 
CYP26A1 Mouse 1:50 Santa Cruz, SC53618 
CYP26B1 Mouse 1:50 Santa Cruz, SC293493 
FLG Mouse 1:75 ThermoFisher MA5-13440 
KRT10 Mouse 1:100 DAKO, M7002 
KRT14 Mouse 1:50 Santa Cruz, SC58724 
2°, HRP-conjugated 
(anti-mouse) 
Horse 1:100 Vectastain, PK-4002 
2°, Alexa Fluor 
488-conjugated 
(anti-mouse) 
Goat 1:1000 Life Technologies, A11001 
Hoechst 33258, 
nuclear stain 
- 1:100 Life Technologies, H3569 
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2.2.6 DIFFERENTIAL GENE EXPRESSION 
2.2.6.1 RNA ISOLATION 
Following treatment, RHEs intended for RNA extraction were flash frozen at -80°C 
until use. RNA was isolated using the NucleoSpin RNA (Macherey-Nagel, 740955) kit, as 
recommended by the manufacturer. Variations from the standard protocol include: 
homogenization with 600µL (rather than 350µL) of RA1 lysis buffer, addition of 6µL of 
β-mercaptoethanol to RA1 to aid tissue lysis, and addition 600µL of 70% ethanol (rather 
than 350µL) during nucleic acid precipitation. 
2.2.6.2 RT qPCR 
Isolated RNA purity and concentration were measured by NanoDrop 2000c 
(Thermo Scientific) and integrity was confirmed by gel electrophoresis. For each reaction, 
6.5µL of a mix containing; 100-200ng of template RNA, 50ng/mL oligo(dT)12-18 (Life 
Technologies, 58862), and 0.5mM dNTP mix (Invitrogen, 
10216018/10219012/10217016/10218014), were incubated at 65°C for 5min. 3.5uL of the 
Superscript III reverse transcriptase kit (Invitrogen, 18080044), which includes enzyme 
(56575), DTT (Y00147), and 5x first-strand buffer (Y02321), is then added to each well 
and incubated for 50min at 42°C, followed by 15min at 70°C. The cDNA was then diluted 
1:10 with water. 2µL of cDNA was added to a 10µL real-time qPCR reaction, which used 
Takyon No ROX SYBR 2X MasterMix (Eurogentec, UF-NSMT-B0701) on a Roche 
Lightcycler 96 (activation: 3min - 95°C; 40 cycles: 10sec - 95°C, 20sec - 60°C, 30sec - 
72°C). 500nM of each primer pair (Table 2.3), optimized for an annealing temperature of 
60°C, was used for each reaction. RPL13a and 36B4 (RPLP0) were used as reference 
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genes. Every reaction was performed in technical duplicates. Due to limited access to donor 
tissue, and the low cellular passage number necessary for quality RHE, the qPCR results 
obtained during experiment 1 (Table 2.1) consists of pooled data from replicate 
experiments consisting of RHE from several donors. Because these independent replicates 
are subject to the interindividual variability in treatment response by each donor, we 
applied a method described by Willems et al.122 to standardize the qPCR data, determine 
the fold-change in expression from control, and calculate the 95% confidence interval of 
the mean. Statistical analysis was done by one-way ANOVA with Dunnett’s correction for 
multiple comparisons on the standardized values using GraphPad Prism 6. 
Target Forward Reverse Ref 
36B4 
5’-ATC AAC GGG TAC AAA 
CGA GTC-3’ 




5’-CTC AAG GTC GTG CGT 
CTG AA-3’ 




5’-TGG CCC TCC ACT CCT 
CAT C-3’ 
5’-GGG TCA CAG AAC CAT 
CCT AGC T-3’ 
121 
IVL 
5’-TGA AAC AGC CAA CTC 
CAC-3’ 




5’-ATC GAT GAC CTT AAA 
AAT CAG ATT CTC-3’ 
5’-GCA GAG CTA CCT CAT 
TCT CAT AC-3’ 
i 
KRT14 
5’-CGA TGG CAA GGT GGT 
GTC-3’ 




5’-GGG AGA GCG GCT GGA 
CAT-3’ 




5’-CCG CTT CCA TTA CCT 
CCC GTT C-3’ 




5’-GGG CAC TGA AAG GCA 
AAA AG-3’ 
5’-CAC CAT AAT CAT AAT 
CTG CAC TAC CA-3’ 
123 
TGM1 
5’-GTC GTC TTC CGG CTC 
GAA-3’ 
5’-TCA CTG TTT CAT TGC 
CTC CAA T-3’ 
123 
STRA6 
5’-TCC CTG TGT TTG CTG 
CT-3’ 
5’-GAA CAG TCC CAG TAT 
CTT CCA G-3’ 
iii 
Table 2.3: List of primers used for qPCR. Integrated DNA Technologies (IDT) assay 
IDs: i - Hs.PT.58.38635764, ii - Hs.PT.58.38517191, iii - Hs.PT.58.3346779.g. 
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2.2.6.3 RNA SEQUENCING & BIOINFORMATICS 
RNA samples were sent to the University of Colorado’s Genomics and Sequencing 
Core Facility (Denver) for library preparation and sequencing. Purity and concentration 
were measured with an Agilent Bioanalyzer (Agilent Technology). 200-500ng of RNA was 
used to prepare the Illumina HiSeq libraries according to manufacturer’s instructions for 
the TruSeq Stranded RNA kit (Illumina). Sequencing was done as 2x 151bp paired end 
reads on the Illumina HiSeq4000. 
Raw data was delivered to us as FASTQ files (two paired files per sample), which 
contained RNA sequences, each with a length of 151 bases (b), as well as a quality score 
metric (Q) per base read, which indicates the probability (P) that the respective nucleotide 
was incorrectly identified by the sequencer. This score is defined as: 𝑄 = −10 ∙ log 𝑃. 
A sequence score ≥ 30 (indicating a P ≤ 0.001) is typically considered acceptable for 
analysis. As delivered, sequencing across all samples had an average quality score of 35.2 
(lowest quality sample scoring a mean of 34.9 across all sequences), with the total reads 
per sample averaging 12.4Gb (smallest sample size: 9.2Gb).  
The bioinformatics pipeline we used was an adaptation of several previously 
described methods124–130, and was applied in the following sequence: FastQC130 (v0.11.5) 
→ Trimmomatic128 (v0.38) → FastQC → HiSat2129 (v2.1.0) → SamTools131 (v1.8) → 
StringTie125 (v1.3.4d). FastQC analyzes the FASTQ files to determine the quality of the 
reads before, and after, trimming to ensure acceptable read quality for downstream 
analysis. Trimmomatic then processes each sequence within a set of paired FASTQ files 
to remove the adapter sequences, which were added to the RNA fragments during library 
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preparation for sample identification. Trimmomatic also applies quality filtering using a 
sliding window approach to, starting on the 5’ end of the read, scan 4b fragments and trim 
the 3’ end if any group falls below a mean quality score of 15. Trimmomatic was also 
instructed to remove any sequences trimmed below 36b from the dataset, which helps 
prevent false positives during alignment. Trimming resulted in an average of 0.57% (SD = 
0.13%) of the paired sequences being dropped completely, 59.5% (SD = 11.7%) paired 
survivors, 39.5% (SD = 8.6%) forward only survivors, and 0.47% (SD = 0.09%) reverse 
only survivors. The resulting paired read outputs were used for alignment, while unpaired 
sequences were excluded from further analysis. The trimmed paired FASTQ files were 
reanalyzed in FASTQC to confirm sequence quality was maintained during trimming. The 
HiSat2 package was used to align each sequence to a reference human genome (H. sapien 
GRCh38 genome_tran index, provided by the HiSat2 developers132 and indexed with the 
included shell script). HiSAT2 exports a sequence alignment map (SAM)-formatted file, 
which contains information on each alignment including: the sequence aligned, the location 
of each sequence within the genome, the quality of the alignment, the sequence length, and 
more. SamTools is then used to convert the text-based SAM file to a binary alignment map 
(BAM) file to allow annotation and qualification by the StringTie package. StringTie 
accepts a BAM file as well as a gene transfer format (GTF) file (also built by shell script 
included with the GRCh38 genome_tran index), which contains the names and locations 
of known genes, transcripts, introns, and exons in the reference genome. StringTie’s 
network flow algorithm will also identify and account for various isoforms of a given gene, 
even if they are not explicitly defined in the user provided annotation. The final output of 
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StringTie provides a GTF-formatted count table containing the Ensembl ID for each 
transcript, as well as the number of matching sequences in the sample. The StringTie 
developers also provide a small script (prepDE.py), which was used to combine the 
individual GTF files to a single count table formatted as a comma-separated value (CSV) 
file, which contains one gene per row with the gene IDs in the first column, one sample per 
subsequent column, and the number of transcripts found during alignment in each 
corresponding cell. 
This gene count table can then be imported by the R133 (v3.5.2) package 
DESeq2126,127,134 (v1.22.2) for differential expression analysis. DESeq2 was set up to group 
treatment replicates and determine the fold-change in gene expression from the control 
group for each treatment. BiomaRt135 (v2.38.0) was then used to attach the HUGO Gene 
Nomenclature Committee (HGNC) gene symbols to each Ensembl ID. Finally, DESeq2 
normalizes the raw read counts based on the differential read depth for each sample, applies 
logarithmic-fold change shrinkage to correct for effect size using the apeglm136 (v1.4.2) 
algorithm, and computes the false-discovery rate (FDR) statistic with the default 
Benjamini-Hochberg correction for multiple comparisons. The final output consists of one 
CSV file per comparison (treatment) containing one gene per row (annotated with Ensembl 
ID and HGNC symbol) as well as the mean fold-change in expression and FDR statistic 
for each comparison. Individual treatments were then merged (by matching gene IDs) into 
a single CSV containing the fold-change in expression and FDR for every treatment group 
in the study. 
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Treatment groups & sample sizes: Control (0.1% DMSO, n = 5), 1nM atRA (n = 
4), 100nM atRA (n = 4), 1000nM DX314 (n = 3), and 1000nM DX314 + 1nM atRA (n = 
4). The scripts used for bioinformatic analysis can be found here: 
https://github.com/JGSV/DX314_Bioinformatics/. 
2.2.6.3.1 PATHWAY AND REGULATOR ANALYSIS 
The output of the procedure detailed above, which contains each treatment’s mean 
fold-change in expression from control, and their respective FDR values, mapped to 
Ensembl IDs were imported into Ingenuity Pathway Analysis137 (IPA, Qiagen) software 
for pathway analysis. This software utilizes an expert-curated knowledgebase containing 
millions of peer reviewed findings and datasets, to allow for in depth investigation into 
complex biological pathways, networks, regulators, and more. We selected to limit the IPA 
analysis (which used the most up-to-date database available as of January 20th, 2019) to 
only consider genes with an FDR ≤ 0.05 and a fold-change in expression greater than 1.5, 
or less than -1.5. IPA utilizes Fisher’s exact test (we accepted the recommended 
significance cutoff of p ≤ 0.05) to predict which canonical pathways and upstream 
regulators are activated, inhibited, or unaffected. IPA was instructed to only consider 
upstream regulators which fell under the following IPA-provided categories: “genes, RNA, 
proteins, and endogenous chemicals”. The relative strength and direction of each prediction 
is given as a z-score. As per IPA’s recommendation, a z-score of ≥ 2.0 was considered 




2.3.1 DX314 POTENTIATES THE EXPRESSION OF RETINOID-
RESPONSIVE GENES WHEN CO-TREATED WITH 
NANOMOLAR atRA 
In the first series of experiments, RHE made with primary keratinocytes from three 
adult donors were treated with variable doses of atRA or RAMBAs (DX314 or liarozole) 
with, or without 1nM atRA. Alterations in the mRNA expression of several genes related 
to keratinocyte differentiation or retinoid bioactivity were observed using real-time, 
quantitative polymerase chain reaction (RT-qPCR) (Figure 2.2). Due to inherently high 
interindividual and interexperimental variability, the raw data was standardized as 
described by Willems et al.122 across independent experimental replicates. After treatment 
with atRA alone, an increase in HBEGF, CYP26A1 and CYP26B1 expression is observed. 
A subtle, yet significant, increase in expression is also observed in IVL at a dose of 100nM. 
Since culture media does not initially contain RA, RAMBAs alone should exhibit no effect 
if their action is through enhancement of RA concentration. We herein confirm that neither 
DX314 nor liarozole alone had significant effect on the expression of the genes analyzed 
in this study. On the contrary, we found that 1000nM DX314 combined with 1nM atRA 
was able to mimic the consequences of high dose atRA on the expression of every gene 
analyzed here. 100nM DX314 with 1nM atRA also achieved this effect on HBEGF and 
IVL. Liarozole with atRA was only able to significantly alter HBEGF and CYP26A1 
expression but did so each dose studied. Overall, these results do appear to support the 
hypothesis that the RAMBAs potentiate the effect of low dose atRA on these genes, 
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however, we did experience a large variance in the replicates, which, we believe, was due 




Figure 2.2: Variable gene expression of RHE treated with atRA, RAMBAs. 
Expression of HBEGF (a-d), IVL (e-h), CYP26A1 (i-l) and CYP26B1 (m-p) mRNA 
after 4-day treatment with atRA or RAMBAs, with (grey bars), and without (white 
bars), 1nM atRA. Data includes pooled results of RHE grown using keratinocytes from 
one of three donors. Solid line below shows control, while the dotted line shows 1nM 
atRA. Bars show mean ± 95% CI. Significance vs vehicle control determined by one-
way ANOVA with Dunnett’s correction for multiple comparisons on autoscaled 
values. *p≤0.05; **p≤0.01; ***p≤0.001. n = 4 in all groups except: 1000nM DX314 
(with/without atRA) and 2000nM liarozole (with/without atRA); n=3. Note: CYP26A1 
controls showed no detectible fluorescence after 40 qPCR cycles. To allow for 
presentation of data a target Ct value of 40 was assigned to undetected samples. 
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Immunohistochemical staining of the RHE shows IVL primarily localized in the 
upper layers of the epidermis in the control and 100nM DX314 treatment groups (Figure 
2.3). 1nM and 100nM atRA, as well as 100nM DX314 + 1nM atRA, all show earlier IVL 
expression within the lower layers suggesting a modification of differentiation by atRA 
and supporting the potentiating effect of DX314. Immunostaining of CYP26A1 and 
CYP26B1 (Figure 2.4) were also performed but the results were disorganized and 
inconsistent with mRNA expression patterns. Irregularities and a lack of correlation 
between CYP26 mRNA and protein expression has previously been observed in in vitro138 
and in vivo111,139 studies of RAMBA treated ichthyotic and healthy skin.  
Figure 2.3: Changes in involucrin (IVL) localization by atRA, DX314.
Comparison of healthy RHE processed for IHC detection of late differentiation 
marker, IVL, following a 4 day of treatment with atRA, DX314, or DX314 + atRA. 
Scale bar = 20µm. 
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 To address the variance in gene expression seen in in the first series of experiments 
and confirm the ability of DX314 to potentiate the effects of low dose atRA, we designed 
the second series of experiments, to use a single source of healthy, primary keratinocytes 
CYP26A1 
CYP26B1 
Figure 2.4: Immunofluorescent staining of CYP26 in healthy RHE. RHE were 
stained with antibodies targeting CYP26A1 (top, green), CYP26B1 (bottom, 
green), and a nuclear stain (blue). 
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for all replicates. In this experiment, we performed RNA sequencing (RNAseq) which 
allows simultaneous investigation of all expressed transcripts in a sample and quantify 
differential expression across treatments. The RNAseq results confirm that 1000nM 
DX314 alone has no effect on HBEGF, IVL, CYP26A1 or CYP26B1 mRNA expression. 
However, DX314 conversely demonstrates potentiation of atRA effects when cotreatment 
is performed (Figure 2.5). We also present a gamut of known retinoid-responsive genes 
including several keratins (KRT)71, lecithin:retinol acyl- transferase (LRAT)93, retinol 
binding protein 1 (RBP1)140, and cellular retinoic acid binding protein 2 (CRABP2)141 
which also show a potentiation of atRA by DX314. In the adjacent left column of the figure, 
we show whether a particular gene involves direct (green = RAREs present within 
promotor71,100,142–148), or indirect/unknown (white = no known RAREs in promotor) RA 
pathways. Overall, the RNAseq experiment displays gene expression patterns which 





Figure 2.5: Gene expression by RNAseq in RHE treated with atRA, 
DX314. Fold-change in expression vs vehicle control. RHE treated with 1nM 
atRA (left column), 100nM atRA (middle-left column), 1000nM DX314 
(middle-right column), or 1000nM DX314 + 1nM atRA (right column). Dark
grey cells indicate a lack of statistical significance, while all colored cells are 
considered statistically significant (FDR ≤ 0.05). An adjacent green box 
indicates the gene shows evidence of RAR-mediated expression effects based 
on RA response elements (RAREs) found within the promotor region. 
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2.3.2 DX314 INDEPENDENTLY MITIGATES RHE BARRIER 
DISRUPTION 
We measured the transepithelial electrical resistance (TEER) of RHE from the first 
series of experiments as a functional measure of barrier integrity. To account for the 
inherent variability across experiments and keratinocyte sources, the results of each 
independent run were pooled and normalized to their respective controls. We observed a 
significant decrease in TEER by atRA (Figure 2.6). Talarozole and liarozole alone showed 
no significant effect on TEER, while cotreatment with nanomolar atRA resulted in a 
significant decrease. Surprisingly, 1000nM DX314 showed an increase in TEER and there 
Figure 2.6: Normalized TEER of RHE treated with atRA, RAMBAs. 
Experiment 1 (groups 1 and 2) RHE following 4-day treatment with atRA or 
RAMBAs with, or without, atRA cotreatment. Data includes pooled results of 9 
independent runs performed during experiment 1. Post-treatment TEER values 
were normalized to the control RHEs within each run. Graph shows Tukey’s 
boxplot with outliers. Sample sizes (n) are shown above x-axis. Significance vs 
the vehicle control determined by one-way ANOVA with Dunnett’s correction for 
multiple comparisons. *p≤0.05; **p≤0.01; ***p≤0.001 
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was no observed decrease in TEER when cotreated with atRA. This is despite our gene 
expression studies indicating a robust potentiation of atRA effects. TEER was measured 
again in the second series of experiments (Figure 2.7a), however, we found that the D11 
(post-treatment) TEER in all groups, apart from 100nM atRA, exceeded the accuracy 
threshold of the instrument (accurate at ≤10,000Ω), so any differences could not be 
resolved. Despite the instrument limitation invalidating any conclusive analysis of the 
results, we believe the initial trends observed on D9 were consistent with, and certainly do 
not contradict, the observations of the first experiment. 
Assessment of TEWL also proved problematic in this study. The experiment was 
performed twice, and the results combined for analysis. Although it initially appeared that 
DX314 treated RHE may have slightly reduced the average TEWL (Figure 2.7b), the 
experiment as performed did not find any statistically significant differences and 
conclusions could not be drawn. 
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Morphologically, atRA treated RHE showed a distinct disruption of normal tissue 
structure (Figure 2.8). Observed changes include a near total loss of the dark, FLG-
containing, keratohyalin granules (KG) typically found in the stratum granulosum (SG), a 
shift in the stratum basale (SB) keratinocytes from a typical columnar appearance to a more 
rounded appearance (more closely resembling SS keratinocytes), a less nucleated stratum 
Figure 2.7: TEER and TEWL of RHE 
treated with atRA, DX314. (a) Raw TEER 
of RHE (experiment 2, group 3) following 
treatment with atRA or DX314 with, or
without atRA cotreatment. Raw TEER of 
D7 (blue, before treatment), D9 (red, 2 days 
of treatment), and D11 (green, 4 days of
treatment) are shown.  Due to TEER 
measurements exceeding the accuracy 
limits of the instrument (rated at 10,000Ω, 
dotted line) in most samples, a proper 
analysis could not be performed. Bars show 
mean±SD. (b) Corrected TEWL values 
from two runs of RHE (experiment 2, group 
4) treated with atRA or DX314 with, and 
without, atRA cotreatment. Black bar 
indicates mean, each point represents a 
single RHE. One-way ANOVA with 
Dunnett’s correction for multiple 
comparisons showed no significant 






spinosum (SS), and an overall unhealthy appearance. RHE treated with liarozole or 
talarozole alone showed no major histological changes, but RHE cotreated with nanomolar 
atRA resemble the RHE treated with high dose atRA. Similarly, DX314 causes no major 
changes in morphology when dosed alone, but unlike the other RAMBAs, we observed 
minimal disruption of normal morphology with atRA cotreatment (intact SG/KG, 
columnar SB keratinocytes, generally healthy tissue appearance). A replication study of 
these effects on RHE morphology by atRA and DX314 showed the same results (Figure 
2.9). When we consider the gene expression profile showing a strong potentiation of low 
dose atRA by DX314, this finding seems to suggest that DX314 displays a subtle protective 
effect on epidermal integrity and may be able to mitigate the more aggressive adverse 





Figure 2.8: Morphological changes in RHE treated with atRA, RAMBAs. RHE 
(experiment 1, group 2) morphology changes after 4-day treatment. 6µm sections 
were stained with H/E. Control RHE consists of columnar keratinocytes in the 
stratum basale (SB, bottom layer), flattened cells in the stratum spinosum (SS, 
second layer), a thick stratum granulosum (SG, third layer) with many keratohyalin 
granules (KG, stain as a dark grainy texture within SG), and a relatively thin but 






























































































































































The epidermal differentiation complex (EDC) is a cluster of genes, found on human 
locus 1q21, that are essential for epidermal differentiation149. We mapped the expression 
of these genes, as well as some known EDC gene expression regulators, to the RNAseq 
data we collected (Figure 2.10). Overall, the expression patterns appear to be consistent 
with observations of other retinoid-responsive genes previously discussed. However, we 
did observe that the expression of many genes in the cornified envelope precursor family 
were not affected by DX314 + atRA treatment despite a dramatic downregulation by high 
dose atRA. We speculate that a preservation of cornified envelope protein expression may 
be a factor contributing to the increase in TEER observed in DX314 treated RHE. 
Investigation into whether this observation directly contributes to the barrier effects we 




Figure 2.10: Fold-change in expression 
of epidermal differentiation complex 
(EDC) genes. RNAseq results from RHE 
(experiment 2, group 3) treated for 4 days 
with atRA, DX314. Adjacent column 
(left side) separates genes by the three 
major EDC groups (light blue, pink, 
purple). We also show expression of 
several known EDC regulators (green). 
Dark grey cells indicate a lack of 
statistical significance, while all colored 
cells are considered statistically 




2.3.3 PATHWAY AND UPSTREAM REGULATOR ANALYSIS OF 
DX314 AND atRA 
Data from the RNAseq study was then ingested into Qiagen’s Ingenuity Pathways 
Analysis (IPA) software for in silico canonical pathway and upstream regulator analysis. 
We elected to use significance cutoffs of FDR ≤ 0.05 and fold-changes ≥ 1.5 or ≤ -1.5 to 
limit the number of genes used in the analysis. These cutoffs resulted in 1360, 5480, 169, 
and 3015 differentially expressed genes being considered for analysis of 1nM atRA, 
100nM atRA, 1000nM DX314, and 1000nM DX314 + 1nM atRA, respectively. As per the 
recommendations, the pathway regulator predictions by IPA were considered significant if 
the Fisher’s exact p-value was ≤ 0.05, and the z-score was ≥ 2.0 (predicted activation) or ≤ 
-2.0 (predicted inhibition).  
The results of IPA’s upstream regulator analysis were filtered to only include 
“genes, RNA, proteins, and endogenous chemicals”, then sorted by overall |z-score| (Figure 
2.11, left). As expected, the regulator with largest predicted activation was atRA 
(tretinoin), and the predicted activation scores displayed a pattern consistent with a 
potentiation of low-dose atRA by DX314 (i.e. there is no significant activation by DX314 
alone, while DX314 with atRA results in a score exceeding that of atRA alone). Of the top 
20 scoring regulators, only three weakly displayed any predicted activity by DX314 alone 
suggesting minimal effects by DX314 in the absence of atRA. 
Canonical pathway analysis (Figure 2.11, right) found the overall most activated 
(“Integrin Signaling”) and inhibited (“RhoGDI Signaling”) pathways both display 
activation score patterns which suggest a potentiation of low-dose atRA by DX314. 
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Diagrams of these two signaling pathways, as well as the “RAR activation” pathway for 
each treatment can be found in the supplemental data (Supplemental Figure 1, 
Supplemental Figure 2, Supplemental Figure 3). Only a single pathway (“Neuroprotective 
Role of THOP1 in Alzheimer’s Disease”) was found to be modulated by DX314 alone, 
however the effect was weak with the z-score (= 2.0) just meeting the recommended cutoff 
threshold for significance. 
Figure 2.11: Pathway analysis of RNAseq profiles. (left) The top 20 highest scoring 
upstream regulators (including; genes, RNA, proteins, and endogenous chemicals) as 
predicted by IPA. (right) The top 20 highest scoring canonical pathways predicted by 
IPA. A positive z-score (orange) predicts activation, while a negative z-score (blue) 
predicts inhibition. A black dot indicates scores that did not meet the threshold for 




Retinoids are well-established therapeutics for the treatment of many skin 
diseases43,60,64. Despite their efficacy, their use can often lead to adverse reactions in 
patients due to undesirable activity exacerbated by autoinduction of its metabolism and 
tolerance58,150. A strategy involving the use of RAMBAs, which target the RA-inactivating 
CYP26 enzyme, was developed to address these issues. Although preclinical studies and 
clinical trials did show their potential in treating certain skin disorders41,88,112,121,151,89–91,107–
111, first-generation RAMBAs such as liarozole, have not progressed past clinical trials, 
likely due to off-target activity106. Consequently, there remains a strong interest in highly 
selective RAMBAs, with low risk of adverse events, that could address the downsides of 
current treatments.  
Here, we show our novel CYP26B1-selective RAMBA, DX314, can potentiate the 
effects of low-dose atRA in healthy RHE. We investigated the effects of atRA on several 
retinoid-responsive genes compared to DX314 or liarozole, when treated with, or without 
atRA at a nanomolar concentration (Figure 2.2). We confirmed an increase in HBEGF, 
CYP26A1, and CYP26B1 mRNA expression by atRA. Although the effect on IVL 
expression was less robust, we did see a significant increase in IVL expression by atRA at 
a dose of 100nM. Our experiments also show that, when used alone, neither RAMBA had 
a significant effect on the expression of these genes at any dose. DX314 was able to 
significantly potentiate atRA’s effects on HBEGF, IVL, CYP26A1, and CYP26B1 
expression. Liarozole with atRA was only able to significantly alter the expression of 
HBEGF and CYP26A1. Immunostaining confirms the effects of DX314 and atRA on IVL 
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localization (Figure 2.3), however CYP26A1 and CYP26B1 staining (Figure 2.4) was 
found to be irregular and not reflect mRNA expression. Because this anomaly has been 
previously reported in in vivo and in vitro studies of healthy and ichthyotic skin, we do not 
believe it conflicts with our conclusions111,138,139. 
In the initial experiments, replicates were done using RHE grown from different 
donors. This study design ensured that any observed effects must be robust enough not be 
overly sensitive to inter-individual differences, however, this also resulted in large 
variances across independent experimental runs. 
For the design of the second series of experiments we chose to study DX314 and 
atRA in RHE using RNAseq and a single, independent source of primary keratinocytes for 
all replicates. This experiment confirmed the expression effects of atRA, the lack of effect 
with DX314 alone, and the atRA potentiating effect of DX314 on HBEGF, IVL, CYP26A1 
and CYP26B1 expression (Figure 2.5). This experiment also allowed us to investigate the 
effects on many other genes of interest of which the overwhelming majority supported the 
atRA potentiation hypothesis. We observed this pattern in genes regulated by both direct 
(RARE-containing promotor), and indirect RA pathways. Based on these results, we 
conclude that DX314 can potentiate the effects of nanomolar atRA by inhibiting the 
metabolism of RA. 
TEER is a useful method of assessing epidermal barrier integrity in vitro. 
Surprisingly, we found that RHE treated with 1000nM DX314 displayed a significant 
increase in TEER compared to control, and unlike liarozole or talarozole, no decrease in 
TEER when cotreated with low-dose atRA (Figure 2.5). Despite atRA robustly decreasing 
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TEER, and DX314 otherwise appearing to potentiate the gene expression effects of atRA, 
we did not observe deterioration of barrier function in RHE dosed with a cotreatment of 
DX314 and atRA. Replication studies of these TEER effects were inconclusive due to 
instrument limitations (Figure 2.7a), however, we believe the trends observed in the data 
show a pattern consistent with the previous observations. Morphologically, DX314 treated 
RHE appear to show significantly less disruption of the SG and KGs, and display an overall 
healthy appearance compared to high dose atRA or liarozole treated groups (Figure 2.8, 
Figure 2.9). We also found minimal changes in the expression of many corneal layer 
precursor transcripts within the EDC (Figure 2.10), despite a large decrease in expression 
by high-dose atRA, and most retinoid-responsive genes showing DX314 potentiating 
atRA’s effects on gene expression. Whether or not DX314 does protect the skin barrier, 
while also retaining the therapeutic benefits of retinoids, remains to be seen and we cannot 
make a conclusive statement based solely on this study, however, we believe the 
observations made certainly merit further investigation. Additional in vitro and in vivo 
studies utilizing alternative measures of barrier integrity and function may provide 
additional insight into these unique observations. 
Finally, we present the activity of upstream regulators (Figure 2.11, left) and 
canonical pathways (Figure 2.11, right) as predicted by IPA software. The top scoring 
upstream regulator was atRA (i.e. tretinoin) which showed an activation z-score of 5.04 
and 6.90 for 1 and 100nM atRA, respectively. DX314 alone scored below the significance 
threshold at 1.70, but when cotreated with 1nM atRA scored 7.94. This result strongly 
suggests DX314 alone does not significantly affect known RA pathways, but potently 
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potentiates the effects of atRA in cotreated conditions. 16 of the top 20 scoring upstream 
regulators, and 14 of the top 20 scoring canonical pathways showed DX314 with low-dose 
atRA as having an absolute z-score larger than low-dose atRA alone. Overall, these results, 
in conjunction with the previously discussed data, provide further evidence of DX314’s 
ability to potentiate the effects of nanomolar atRA. 
We conclude that the results presented in this study show strong evidence that 
DX314, which is known to inhibit the RA-metabolizing enzyme CYP26B1, potentiates the 
effects of atRA in healthy RHE. We also show compelling evidence that DX314 may 
protect from epidermal barrier disruption by retinoids, and strongly believe these 
observations merit further study.  
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3. DX314 AS A POTENTIAL THERAPEUTIC IN 
KERATINIZATION DISORDERS 
3.1 INTRODUCTION 
Keratinization disorders refer to a class of skin disorders which induce a disruption 
of normal keratinocyte differentiation (keratinization) and resulting in abnormal skin 
development and function. In this study, we expand upon our previous research confirming 
DX314 will potentiate the effects of low-dose atRA, with minimal undesirable off-target 
activity. To determine if these effects will translate from healthy keratinocytes to the 
potentially unique responses of diseased keratinocytes, we investigated DX314 in two 
keratinization disorders which have an established clinical history of effective treatment 
by retinoids. 
In the first series of experiments, we grew RHE using keratinocytes donated by a 
patient with Darier’s disease (DD). Although RAMBAs have not specifically been 
investigated or used for treatment of this disease, retinoids, particularly 13-cis-RA, have 
been used as an effective treatment in DD patients47–49. If the advantages of RAMBAs can 
be shown to be as effective as retinoids in DD, implementing their use may improve 
patients’ outcomes and provide more treatment options to their physicians. For the second 
series of experiments, we studied the effects of DX314 on keratinocytes donated by 
congenital ichthyosis patients. The subtypes investigated in this study include two 
recessive x-linked ichthyosis (RXLI) donors (herein referred to as RXLI-1653 and RXLI-




3.1.1 PRIMARY HUMAN KERATINOCYTES 
Darier’s disease keratinocytes (DARK1) from a male child were donated to the 
project by our collaborator Dr. Yves Poumay at the University of Namur, Belgium. 
Recessive x-linked ichthyosis (RXLI) and lamellar ichthyosis (LI) keratinocytes were 
provided by Dr. Amy Paller at Northwestern University, Illinois. Keratinocytes from three 
ichthyosis patient donors were used in this study: RXLI-1653 (29yo, male), RXLI-1658 
(13yo, male), and LI-173 (details not provided). 
3.1.2 CELL CULTURE 
Refer to Section 2.2.2. 
3.1.2.1 MONOLAYER AUTOCRINE KERATINOCYTES 
Culture of monolayer RXLI keratinocytes was performed by the Paller lab and is 
adapted from a method described by Poumay et al.123. In short, 25,000-50,000 
keratinocytes (prepared as described in Section 2.2.2) are seeded in 6-well cell culture 
plates containing 2mL of Epilife Complete and placed in a 37°C, 5% CO2, humidified 
incubator. The media is changed every two days until ~60% confluent, at which point the 
media is replaced with Epilife Autocrine (Epilife media, 0.5% P/S, 0.5µM hydrocortisone, 
240µM L-histidine, 750µM L-isoleucine, 90µM L-methionine, 90µM L-phenylalanine, 
45µM L-tryptophan, 75µM L-tyrosine), which does not contain any HKGS, for the 
remainder of the experiment. This autocrine formula allows for the investigation of 
epidermal differentiation markers, which can otherwise be affected by growth factors 
present in non-autocrine media, using monolayer keratinocyte cultures. The keratinocytes 
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continue to proliferate in autocrine conditions, and the media changed every two days, until 
100% confluent. Once all the wells in an experimental group reach confluence, treatments 
are added to fresh Epilife Autocrine (final concentration of 0.1% DMSO as vehicle), 
applied to each well, and allowed to incubate for 20hrs. After the 20hr treatment, the media 
is aspirated from each well and 500µL of TRIzol (Thermo, 15596-018) is immediately 
added. The cells are homogenized, and the lysate is flash frozen at -80°C until shipped to 
us on dry ice for RNA isolation. 
3.1.2.2 RECONSTRUCTED HUMAN EPIDERMIS 
Refer to Section 2.2.2.1. 
3.1.2.3 ORGANOTYPIC RAFTS 
Organotypic rafts were grown by collaborators at the Paller Lab (Northwestern 
University) using a previously described protocol152. The protocol here is described per raft 
so all components were scaled according to the number of rafts within each experiment. 
For each raft, 4e5 J2-3T3 fibroblasts are suspended in 150µL of 10x reconstitution buffer 
(22µg/mL NaHCO3, 46µg/mL HEPES in 0.05N NaOH then 0.2µm sterile filtered). On 
ice, 150µL of 10x DMEM is then added, followed by 6mg of rat tail collagen I (BD, 
354249), which is rocked gently until color changes to yellow indicating the solution is 
acidic. We then add 0.5N NaOH until the pH becomes neutral and the solution is brought 
up to 1.5mL (per raft) with sterile ddH2O. 1.5mL of the collagen suspension is added to a 
well of a 12-well plate and placed in a 37°C incubator for 30min to polymerize, after which 
an additional 3mL of media is added to the top of each plug. This is then incubated at 37°C 
for at least 24hrs before keratinocytes can be added. After 1-4 days, media is removed from 
72 
 
each plug and replaced with 1mL of E media [180µM adenine (Signa, A2786), 5µg/mL 
human recombinant insulin (VWR, 91077C), 5µg/mL human apo-transferrin (Sigma, 
T1147), 5µg/mL triiodothyronine T3 (Sigma, T6397), 0.25µg/mL Amphotericin B 
(Cellgro, 30003CF), 4nM L-glutamine (Sigma, G7513), 0.4µg/mL hydrocortisone (Sigma, 
H0888), 10ng/mL Cholera toxin (Sigma, C8052), 5% FBS (Fisher, SV30014.03), in 1:1 
mix of DMEM HG (Sigma, D5671): DMEM/F-12 (Sigma, D6421)] supplemented with 
5ng/mL EGF. For each raft, suspend 6e5 keratinocytes in 1mL E media + 5ng/mL EGF 
and add this suspension to the top of a collagen plug. The media is refreshed after 24hrs. 
After two days, a sterile spatula is used to transfer each raft to the top of a sterile metal grid 
in a 60mm plate. Enough media is added so that only the bottom of the raft is submerged, 
and an air-tissue interface is established on the surface (~4-5mL). The rafts are placed in 
an incubator and media is maintained every two days until the experiment is complete. As 
with the RHE, treatments (0.1% DMSO vehicle) are done over four days and refreshed 
after two days. Rafts intended for RNA isolation are then lysed in 500µL TRIzol and stored 
at -80°C until shipped to us on dry ice for RNA isolation. 
3.1.3 TEWL 
Refer to Section 2.2.3. 
3.1.4 TEER 
Refer to Section 2.2.4. 
3.1.5 HISTOLOGY & IMMUNOSTAINING 
Refer to Section 2.2.5. 
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3.1.6 DIFFERENTIAL GENE EXPRESSION 
3.1.6.1 RNA ISOLATION 
Isolation of RNA from RHE groups was performed as described in Section 2.2.6.1. 
RNA obtained from monolayer and organotypic raft cultures were isolated using 
TRIzol (phenol-chloroform extraction) as described by the manufacturer. Variations from 
the standard protocol include chilling the sample following the addition of isopropanol to 
encourage nucleic acid precipitation, and the addition of a second chilled 75% ethanol wash 
prior to drying the pellet, which greatly improved consistency in RNA purity. 
3.1.6.2 RT QPCR 
DD RHE study was performed as described above (Section 3.1.6.2) Remaining 
groups in this study were done with several variations from the previously described 
method which are described here:  
A 10µL reverse transcription was done with 100-200ng of template RNA using 
qScript cDNA Supermix (QuantaBio, 95048) with the following incubations: 5min 25°C, 
30min 42°C, 5min 85°C. The cDNA was then diluted 1:10 with water and 2µL was added 
to a 10µL real-time qPCR reaction, which used PerfeCTa SYBR Green Supermix, Low-
ROX (QuantaBio, 95056) on a Stratagene Mx3005P (Agilent Technologies) or CFX384 
(Bio-Rad). Program is as follows (40 cycles): 30sec 95°C, 60sec 60°C, 60sec 72°C. 
Statistical analysis was done by one-way ANOVA with Dunnett’s correction for multiple 
comparisons on the standardized (DD RHE), or raw dCt (remaining experimental groups), 





3.2.1 DX314 IN DARIER’S DISEASE RHE 
DD RHE were investigated by the same experimental methodologies used for the 
previously described healthy RHE studies (Section 0). As expected, atRA treatment 
produced an increase in HBEGF and CYP26A1 gene expression, and a decrease in KRT10 
expression (Figure 3.1). The potent RAMBA talarozole significantly potentiated the effects 
of all genes analyzed, at all doses studied. DX314 was able to significantly potentiate 
effects of atRA on both KRT10 and CYP26A1 expression. However, despite indicating a 
higher average fold-change in HBEGF gene expression, RHE treated by DX314 with low-
dose atRA did not reach the predefined threshold for statistical significance. Due to the 
precious nature of the DD keratinocytes, we were limited in the number of replicates which 
could be used for qPCR analysis which resulted in low statistical power. This small sample 
size likely explains the lack of a statistically significant change in HBEGF expression 
despite a significant modulation of this gene observed in our previous studies. 
Histological analysis shows atRA inducing robust morphological changes in DD 
RHE (Figure 3.2, left column) which reflected those seen in healthy RHE (Figure 2.8). 
RHE treated with atRA showed a dramatic loss of the SB (and KGs typically contained 
within), denucleation and flattening of SS keratinocytes, and an overall unhealthy 
appearance. When treated alone, DX314 and talarozole showed no major morphological 
changes, however addition of nanomolar atRA shifted the appearance, most notably the 
SG/KG, to more closely resemble high dose atRA. Visualization of FLG localization 
(Figure 3.2, middle left column) shows, as we would expect, expression largely isolated to 
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the granular and corneal layers of the epidermis. Treatment with atRA results in a decrease 
in FLG staining relative to control. Talarozole alone displays similar FLG staining to 
control, while talarozole with atRA shows expression levels resembling high dose atRA. 
Conversely, DX314 appears to display significantly increased FLG relative to control, an 
observation which may contribute to the increase in TEER seen in the DX314-treated RHE 
from our previous study (Section 2.3.2). DX314 with 1nM atRA shows FLG levels 
mimicking those of high dose atRA which suggests DX314 is potentiating the effect of 
atRA on FLG staining. KRT14, a cytokeratin typically isolated to basal keratinocytes, 
shows decreased staining following atRA treatment, no significant change following 
treatment by DX314 or talarozole, and diminished expression when RAMBAs are 
cotreated with atRA (Figure 3.2, middle column). Finally, KRT10, a commonly used 
marker of epidermal differentiation typically localized within the suprabasal epidermis, 
shows delayed expression in atRA treated RHE. This seen as an apparent migration of 
KRT10 staining away from the lower layers, and more isolated to the apical layers of the 
epidermis (Figure 3.2, middle right column). When treated alone, the RAMBAs studied 
here show no change in KRT10 localization relative to control, however, when cotreated 
with low dose atRA, staining is diminished in the lower layers and only seen in the more 
apical layers. Overall, this study of DD RHE histology presents compelling evidence that 





Figure 3.1: Gene expression in DD RHE treated with atRA, RAMBAs. 
Differential expression of HBEGF (a-c), KRT10 (d-f), and CYP26A1 (g-i) 
transcripts after 4-day treatment with atRA or RAMBAs, with (grey bars), and 
without (white bars), 1nM atRA. Solid line shows control and dotted line shows 
1nM atRA RHE. Significant changes vs control determined by one-way 
ANOVA with Dunnett’s multiple comparisons correction on autoscaled values. 
*p≤0.05; **p≤0.01; ***p≤0.001. Graphs show mean ± 95% CI.  n = 3 per 
treatment. Note: CYP26A1 control showed no detectible signal after 40 cycles 








































































































































































































3.2.2 DX314 IN ICHTHYOTIC KERATINOCYTE CULTURES AND 
3D EPIDERMIS 
Recessive X-linked ichthyosis (RXLI-1658) patient keratinocytes were grown in 
monolayer cultures and differentiated under autocrine conditions. Cultures were treated for 
20hrs with atRA or RAMBAs (DX314 or liarozole) with, and without, atRA cotreatment 
before RNA was extracted for subsequent RT-qPCR. RXLI-1658 monolayer cultures 
showed DX314 (100 and 1000nM doses) and liarozole (all doses) can potentiate the effect 
of 1nM atRA on the expression HBEGF and CYP26A1 (Figure 3.3) transcripts. DX314 
only appeared to potentiate atRA’s effect on KRT10 and FLG gene expression at the 
highest doses tested, however, we also found that 10nM DX314 alone increases their 
expression. This subtle, but significant, increase likely lessens the decrease in expression 
we would expect when inhibiting atRA metabolism. This may explain why only the highest 
DX314 dose displayed gene expression changes exceeding those of 1nM atRA alone. 
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To investigate how DX314 would perform in RXLI organotypic skin models, rafts 
were grown using RXLI-1653 keratinocytes which were given a 4-day drug treatment 
before RT-qPCR was performed on the isolated RNA. Consistently with our previous 
studies, atRA induced an increase in HBEGF and CYP26A1 gene expression (Figure 3.4). 
Figure 3.3: Gene expression 
effects in RXLI-1658 
keratinocyte cultures. 
Keratinocytes from a patient 
with recessive x-linked 
ichthyosis (RXLI) were grown 
to confluence in autocrine 
conditions and exposed to a 
20hr treatment before RT-qPCR 
was performed. Expression of 
HBEGF, KRT10, CYP26A1, 
and FLG genes are shown. 
Significant changes in 
expression vs control was 
determined by one-way 
ANOVA with Dunnett’s 
correction for multiple 
comparisons on dCt values. 
*p≤0.05; **p≤0.01; 
***p≤0.001. n = 3. Bars show 
mean ± 95% CI. 
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Contrarily to our previous observations, DX314 and liarozole appeared to slightly increase 
HBEGF gene expression in the absence of atRA. This unexpected effect was also seen on 
the expression of CYP26A1 transcripts when the rafts were treated with liarozole, but not 
DX314. However, when cotreated with low dose atRA, an unmistakable potentiating effect 
was still seen by both RAMBAs in both genes. 
Figure 3.4: Gene expression in RXLI-1653 organotypic rafts. Rafts 
grown with keratinocytes from an RXLI patient were treated for 4-days. 
Expression of HBEGF and CYP26A1 genes was measured by RT-qPCR. 
Significant expression changes vs control was determined by one-way 
ANOVA with Dunnett’s correction for multiple comparisons on dCt 
values. *p≤0.05; **p≤0.01; ***p≤0.001. n = 3 per treatment. Bars show 
mean ± 95% CI. 
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Our final study of DX314 in diseased keratinocytes was performed in RHE grown 
with lamellar ichthyotic (LI) donor keratinocytes. We analyzed the expression of several 
of the retinoid-responsive genes we had previously studied. As expected, CYP26A1, 
CYP26B1, HBEGF, and KRT10 transcripts displayed a change in expression by atRA 
(Figure 3.5). In agreement with our immunolabeling of DD RHE (Figure 3.2), atRA 
treatment decreased KRT14 mRNA expression in the LI RHE. Stimulated by retinoic acid-
6 (STRA6), a gene with a strong RARE-mediated response to RA treatment, also saw a 
robust increase in expression by atRA. Expression of TGM-1, a transglutaminase 
responsible for cross-linking the structural proteins of the cornified envelope, was 
decreased by atRA. In all the genes investigated here, 1000nM DX314 alone had no effect 
on gene expression, however, unlike our previous studies, only CYP26A1 and STRA6 
showed expression patterns suggesting a potentiation of low dose atRA by DX314. The 
effects of DX314 with lose-dose atRA do not appear to be significantly different from low 
dose atRA alone for CYP26B1, HBEGF, TGM1 or KRT14 expression. 
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In the same study of LI RHE, we concurrently investigated the effect treatments on 
TEER and TEWL to their effects on epidermal barrier integrity. As we originally 
discovered in healthy RHE (Figure 2.6), we see atRA decreased TEER, while DX314 
independently increased TEER and mitigates atRA’s effect on TEER when cotreated 
(Figure 3.6a). As a secondary measure of barrier function, we also measured the TEWL of 
the RHE following the 4-day treatment. In support of our TEER observations, we find 
atRA induces a robust effect on this measure of barrier function, however, we did not find 
that DX314 had any significant effect on TEWL, nor did it mitigate the effects of low-dose 
Figure 3.5: qPCR of LI-173 
RHE treated with DX314, 
atRA. RHE were treated for 4 
days before measuring relative 
changes in expression of several 
genes of interest by RT-qPCR. 
Significant expression changes vs 
control was determined by one-
way ANOVA with Dunnett’s 
correction for multiple 
comparisons on dCt values. 
*p≤0.05; **p≤0.01; ***p≤0.001. 
n = 3 per treatment. Bars show 
mean ± 95% CI. 
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atRA in cotreatment conditions (Figure 3.6b). Finally, since we simultaneously measured 
both TEER and TEWL on the same RHE, we analyzed the two metrics together to see if 
there exists a correlation between the two measures of barrier function. We show that, 
within the range of the TEER and TEWL values of these RHE, there exists an inverse linear 
relationship between the two, and each treatment tends to cluster with its replicates (Figure 
3.6c). 
Figure 3.6: TEER and TEWL 
of LI RHE treated with 
DX314, atRA. Raw, post-
treatment TEER (a), TEWL (b), 
and the linear correlation 
between the two (c) following 
treatment. Significant changes 
vs control determined by one-
way ANOVA with Dunnett’s 
correction for multiple 
comparisons. *p≤0.05; 




Investigating the treatment effects on RHE tissue morphology shows LI RHE 
reacting to atRA and DX314 in a manner nearly identical to the changes seen in our studies 
of healthy and DD RHE. High dose atRA leads to a significant reduction in SG thickness 
and KG presence and displays an overall unhealthy appearance (Figure 3.7). RHE treated 
with DX314 with, and without low dose atRA, show minimal histological changes relative 
to control, although there does appear to be a slightly more continuous presence of KG 
across the SG. 
Figure 3.7: Morphology of LI RHE treated with DX314, atRA. HE stained LI 




Darier’s disease (DD) and congenital ichthyosis are keratinization disorders with a 
well-established history of effective treatment by retinoid-based therapies41,45,47,48,50,88. As 
previously discussed, excessive retinoid use often results in adverse effects and drug 
tolerance despite their proven efficacy. In this series of experiments, we expand upon the 
work done in our previous studies which show DX314’s effects in healthy in vitro RHE. 
With the help of two of our collaborators, we investigated whether DX314 can also mimic 
the desirable effects of proven therapies in diseased keratinocytes. 
In the DD portion of this study, atRA treatment resulted in an increase (HBEGF, 
CYP26A1), or decrease (KRT10), in gene expression consistent with our hypothesis 
(Figure 3.1).  DX314, as well as the potent RAMBA talarozole, were able to significantly 
potentiate the effects of a low dose atRA cotreatment on the gene expression of KRT10 
and CYP26A1. Statistically speaking, the expression of HBEGF was only significantly 
modified by talarozole, however, we do not believe the effect of DX314 should be 
discounted despite the lack of statistical significance. Due to the rarity of DD, sourcing 
additional donors is quite difficult, and the necessarily low number of cellular passages 
required for quality RHE limited the number of replicates possible. These limitations led 
this experiment to have inadequate statistical power considering the relatively small effect 
size of the treatments on HBEGF expression. Considering the mean change in HBEGF 
expression in this experiment is consistent with expectations and our multiple previous 
studies showing DX314 potentiating the effect of atRA its expression, we suggest these 
results are still in support of our overarching hypothesis. 
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Histological imaging shows 
DD RHE having distinct 
morphological differences compared 
to healthy RHE (Figure 3.8). We can 
see that DD RHE lack the columnar 
keratinocytes characteristic of the SB, 
have a greatly diminished SG, 
increased acantholysis (intercellular 
gaps due to poor cell-cell adhesion), 
and the presence of corps rond 
(abnormal keratinocyte, red circle) which are characteristic traits of DD epidermis in vivo45. 
This study found that DD RHE morphology is affected by the treatments in a nearly 
identical manner to our previous studies of healthy RHE. Treatment with atRA caused a 
loss of the SG, a reduction in epidermal thickness, and denucleation of the SS (Figure 3.2, 
left column). Both DX314 and talarozole show no significant histological effect alone, 
however, low-dose atRA cotreatment results in the tissue morphology mimicking high-
dose atRA treated RHE. 
As we would expect, FLG staining correlated with the loss of SG by atRA, and as 
such, also supports a potentiation of atRA by RAMBAs, however, we also found that 
DX314 appears to independently increase the prevalence of FLG (Figure 3.2, middle left 
column). We did not initially expect this, however FLG’s critical role in tight junction 
formation within the SG may contribute to, and partially explain, DX314’s previously 
Figure 3.8: RHE grown with healthy (top) or 
DD (bottom) keratinocytes. Red circle shows a 
corps rond (round body) keratinocyte, commonly 
found in DD epidermis. Scale bar = 20µm. 
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described ability to increase TEER (Figure 2.7, Figure 3.6). Although we did not 
investigate KRT14 gene expression in DD RHE, we know it to be controlled by RAREs153 
and our previous study showed KRT14 downregulated by atRA in healthy RHE (Figure 
2.5). For these reasons, we investigated KRT14 localization in DD RHE and found that 
atRA does induce a decrease in KRT14 staining, RAMBAs alone show no significant 
effect, and RAMBAs cotreated with atRA show a decrease in staining (Figure 3.2, middle 
column). KRT10 is not directly controlled by RAR as it does not contain a RARE 
promotor, however, its expression is well established as a marker of keratinocyte 
differentiation and highly sensitive to retinoid treatment. We found KRT10 localization in 
the control and RAMBA alone groups to begin just above the basal layer keratinocytes and 
continue into the upper layers of the epidermis (Figure 3.2, middle right column). When 
treated with atRA, or RAMBAs with low-dose atRA, we observe a shift in KRT10 
localization to only the upper layers of the epidermis with significantly reduced staining in 
the SS. Additionally, this reduction in KRT10 staining by the treatments is consistent with 
the observed decrease in KRT10 mRNA expression (Figure 3.1). These studies show the 
effects observed in healthy RHE are translatable to DD RHE, and that DX314 also 
potentiates low dose atRA in this disease. Together this suggests DX314 may have 
potential as an effective treatment strategy for Darier’s disease patients. 
In the congenital ichthyosis portion of this study, we investigated the effects of 
atRA and DX314 in various in vitro experiments using keratinocytes donated by two 
recessive X-linked ichthyosis (RXLI) patients and a lamellar ichthyosis (LI) patient. 
Investigation of gene expression changes after a 20hr treatment of differentiated monolayer 
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RXLI-1658 keratinocytes shows DX314, as well as liarozole, potentiating the effects of 
low-dose atRA on HBEGF, KRT10, CYP26A1, and FLG gene expression (Figure 3.3). 
We did, however, only observe a significant potentiation of HBEGF and CYP26A1 
expression at 100nM and 1000nM DX314, while KRT10 and FLG expression were only 
potentiated with a 1000nM dose. Surprisingly, we also found 1000nM DX314 and 1000nM 
liarozole independently increasing HBEGF and CYP26A1 expression in the absence of 
atRA cotreatment. This observation is inconsistent with our previous studies which did not 
see any such effect by RAMBAs alone. It is possible that this is the result of a unique 
property of monolayer cultures, which is not seen in 3D epidermis; however, we believe it 
is more likely that a sub-nanomolar concentration of atRA, or a RA precursor, was present 
in the media of those samples, and was subsequently potentiated by each RAMBA. We 
also see that 10nM DX314 appears to increase KRT10 and FLG gene expression. Although 
this increase in structural proteins may be partially contribute to the increase in barrier 
function previously described, we did not observe an effect on these genes in DD RHE, or 
in the previous RNAseq study of healthy RHE, so it is likely that this effect is specific to 
monolayer cultures and does not translate to the 3D epidermis models which better reflect 
in vivo conditions. 
Our investigation of RXLI-1653 organotypic rafts also show HBEGF and 
CYP26A1 gene expression was increased by atRA treatment (Figure 3.4). We also show 
that both DX314 and liarozole at 1000nM potentiate the effects of low dose atRA on these 
genes together reinforcing our hypothesis. Despite this, we again observe that 1000nM 
DX314 has a subtle effect on HBEGF expression, while 1000nM liarozole shows a robust 
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effect on both genes in the absence of atRA. These RXLI rafts, as well as the previous 
RXLI monolayer studies, were performed in unison, so it is possible that the discrepancies 
of both can be explained by a presence of retinoids in the media, as previously suggested. 
Replication of these studies was not possible within the timeframe of this dissertation; 
however, additional experiments have already begun and should help determine if this is 
indeed a possibility. 
Finally, we investigated the gene expression and barrier effects of DX314 in LI-
173 RHE.  As predicted, gene expression analysis shows an effect by atRA, and no effect 
by DX314 alone on all genes investigated (Figure 3.5). We confirm DX314 potentiates the 
effects of low-dose atRA on the RARE-promoted CYP26A1 and STRA6 genes, however, 
unlike our previous studies, DX314 was not able to significantly affect the expression of 
the other genes presented any more than low-dose atRA alone. We are unsure as to why 
these genes were not potentiated by DX314 as we would have expected. It is possible that 
the genetic differences of this LI donor result in truncated effects relative to the other 
donors, however, in that case we would expect to be see this reflected in RHE treated with 
atRA alone as well. Another possibility is that RA metabolism in this LI donor has an 
increased propensity to undergo alternative, compensatory pathways and therefor the 
specific inhibition of CYP26 does not reduce the inactivation RA enough to affect the 
expression genes less sensitive to modulation by RA. This may explain why we see the 
expected effects in CYP26A1 and STRA6 expression, but not the others. Finally, this lack 
of agreement with previous studies may be significantly more complicated than a single 
variable can account for and it may be the result of a complicated series of genomic and 
90 
 
non-genomic effects specific to this donor. In any case, we do not believe that this lack of 
RA potentiation in these specific cases invalidates our general hypothesis. It may merely 
suggest that, like many other drugs, the efficacy of RAMBAs are subject to interindividual 
variability and situational differences, meaning they may not universally work in all 
patients and disorders. 
To further gather evidence of the barrier protecting effect of DX314 first observed 
in our studies of healthy RHE  (Section 2.3.2), we measured post-treatment transepithelial 
electrical resistance (TEER) and trans-epidermal water loss (TEWL). We confirm atRA 
decreases, while DX314 independently increases TEER, suggesting a respective decrease 
and increase in barrier function, in LI RHE (Figure 3.6a).  
We simultaneously investigated the effects treatments have on TEWL which show 
atRA significantly increasing water loss, suggesting a decrease in barrier function (Figure 
3.6b). However, our investigation did not find that DX314 had a significant effect on 
TEWL, nor did it show DX314 mitigating the increase in TEWL by atRA. Because water 
transport across the epidermis is a complicated process, it is possible that changes in TEWL 
are partially mediated by water transporters such as aquaporins (AQP), rather than a direct 
reflection of overall barrier integrity. To see if this may be a possibility, we reviewed our 
previously obtained RNAseq data of healthy RHE. We found three water transporters 
(AQP3/5/9) were significantly affected by at least one treatment group (Figure 3.9). 
Notably, we see that all three aquaporins show decreased gene expression in the high dose 
atRA group, AQP3 expression slightly, but significantly, increased in the DX314 group, 
and AQP3 and AQP5 increased in the DX314 with atRA cotreatment RHE. Since altered 
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expression of AQPs have been correlated with altered TEWL154,155, a decrease in AQP 
expression, as seen in high-dose atRA, may result in decreased in TEWL. Despite this, we 
showed high-dose atRA significantly increasing TEWL which suggests high-dose atRA 
may disrupt barrier function to a larger extent than the TEWL data alone suggests. More 
importantly, an increase in AQP expression, as seen in low dose atRA, and DX314 with, 
and without atRA cotreatment, may result in TEWL to increase even if gross barrier 
function itself is not significantly compromised. This 
may explain why DX314 did not appear to 
significantly decrease TEWL, despite appearing to 
reinforce barrier function in TEER and histological 
analysis. It should be noted that the AQP expression 
shown here is from a previous, independent study in 
healthy RHE, and may not directly translate to the 
TEWL results of this study. Additionally, we show 
that there exists an imperfect, but obvious, inverse 
linear relationship (R2 = 0.6568) between the TEER 
and TEWL of an RHE (Figure 3.6c). This suggests 
that, in general, when one measure is altered by an 
external influence, the other tends to be affected as well. 
In summary, these studies of DX314 in diseased keratinocytes show DX314 
potentiates the effects of atRA like we previously observed in healthy RHE, however, this 
was not always the case. DX314 potentiates atRA in DD RHE and RXLI organotypic rafts. 
AQP3 AQP5 AQP9
1nM atRA 1.19 3.27 -1.11
100nM atRA -1.38 -4.16 -2.12




Figure 3.9: Aquaporins with 
significant changes in gene 
expression by DX314, atRA. Fold-
change in expression of aquaporins 
(AQP) found to be significantly 
altered by treatments in healthy 
RHE by RNAseq. Grey cells 
indicate non-significant change in 
expression (significance cutoff: 
FDR ≤ 0.05)   
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In RXLI monolayer cultures, DX314 at higher doses successfully potentiated the effects of 
low dose atRA. Finally, LI RHE did show a DX314 potentiating atRA but only in the 
expression of certain genes (i.e. CYP26A1, STRA6). Most interestingly, we were able to 
successfully replicate the barrier reinforcing effects by DX314 first described in our studies 
of healthy RHE. This indicates that DX314 does in fact display possess some sort of barrier 
reinforcing property which acts independently of many of the atRA-mediated effects we 
describe. 
We conclude there exists substantial evidence to warrant further investigation into 
the therapeutic potential of DX314, not only in the treatment of retinoid-responsive skin 




4. CONCLUSIONS AND FUTURE DIRECTIONS 
The primary intention of this research is to assess the therapeutic potential of the 
novel CYP26B1-selective retinoic acid metabolism blocking agent (RAMBA), DX314 
through a series of in vivo studies. As the primary disease targets of these compounds are 
keratinization disorders, this was accomplished by characterizing the biological effects of 
DX314 in several 2D and 3D cultures of healthy and diseased human keratinocytes. We 
compare DX314 to several compounds with known therapeutic efficacy including the 
endogenous retinoid, retinoic acid (RA), and the two well-studied RAMBAs liarozole and 
talarozole. 
Keratinization disorders are a heterogenous family of skin diseases related to 
abnormal proliferation and differentiation of epidermal keratinocytes. In this study we 
investigate DX314 in two such disorders, Darier’s disease and congenital ichthyosis, 
however, it should be noted that retinoids have been studied, and/or clinically used in a 
wide gamut of dermatological disorders (psoriasis, acne, etc.), as well as several other 
diseases (cancer, neurodegenerative disorders, and more). This wide range of therapeutic 
applications for compounds affecting retinoid biopathways may allow DX314 to be applied 
in the treatment of a plethora of other diseases. 
As previously discussed, there already exist several different treatments which take 
advantage of the role retinoids in regulating keratinocyte proliferation and differentiation. 
The primary strategy of many of these treatments is the direct activation of the target 
biopathways, typically via retinoic acid receptor (RAR) agonism. Both endogenous (e.g. 
retinol, retinal, tretinoin) and synthetic (e.g. adapalene, tazarotene, etretinate) retinoids that 
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utilize this strategy are commonly used, however they can often result in mild-to-severe 
adverse effects. These adverse effects are often exacerbated by the homeostatic 
autoregulation mechanisms controlling endogenous retinoids such as metabolic 
autoinduction (leading to tolerance), and directly influencing the activity or expression of 
factors directly involved in retinoid biopathways. 
The second strategy involves indirectly modulating endogenous retinoid activity by 
RAMBAs (e.g. liarozole and talarozole) which function by inhibiting RA metabolism. This 
strategy aims to address many of the issues surrounding direct-acting retinoids in two 
fundamental ways: 1. They negate the autoinduction of RA-metabolizing enzymes by 
inhibiting their activity, reducing drug tolerance; 2. Extending endogenous retinoid 
activity, without needing high-doses of exogenous retinoids, which greatly reduces the risk 
of adverse effects caused by excessive retinoid use. 
Liarozole is the most thoroughly studied RAMBA and underwent clinical studies 
for skin disorders including ichthyosis and psoriasis, as well as prostate and breast 
cancer156. It was found to be quite effective at alleviating patient symptoms in both 
ichthyosis (Figure 1.12) and palmoplantar pustular psoriasis109, however despite advancing 
to phase III clinical trials, it has not received FDA approval for clinical use, likely due to 
its lack of CYP26 specificity (inhibitor of steroid biosynthesis, as well as several CYPs)157. 
Relative to liarozole, talarozole is a significantly more potent CYP26 inhibitor, and showed 
similar promise in the treatment of several skin diseases, however, it too has not proceeded 
past clinical trials. 
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Because the first-generation RAMBAs have not been approved for medical use in 
the US, there remains a need for a highly specific, efficacious treatment alternative that 
addresses the problems associated with direct retinoid therapy. This lead Diaz et al. to begin 
developing a library of compounds aimed at specific inhibition of CYP26-mediated RA 
metabolism, with minimal undesirable non-specific effects. These compounds were 
designed around the notion that the azole moiety in previous RAMBAs likely contributed 
to their off-target activity by interacting with the heme found in other CYPs, as well as 
other endogenous enzymes. The compounds designed by Diaz et al. do not contain an azole 
group, but still function as CYP26-inhibitors. Early pilot studies identified DX314, among 
other compounds, as promising leads for further study which led us to run the studies 
presented in this dissertation. 
Altogether, these studies conclusively show DX314 successfully potentiates the 
effects of atRA in in vitro models of healthy, Darier’s disease, and ichthyotic epidermis, 
while showing minimal evidence of undesirable off-target activity. Since the primary 
biological activity of retinoids is related to its nuclear receptor-mediated effects of gene 
expression, we investigated the gene expression changes of treatments using RT-qPCR and 
RNA sequencing studies. Several independent experiments comparing the effects of atRA 
and RAMBAs with, and without, low-dose atRA confirmed DX314’s ability to potentiate 
the effects of atRA on gene expression in a similar manner to well-studied RAMBAs, with 
minimal observations of expression changes indicating off-target activity (Figure 2.2, 
Figure 2.5, Figure 2.10, Figure 3.1, Figure 3.3, Figure 3.4). Pathway and upstream regulator 
analysis were also done on the RNAseq study results (Figure 2.11). The most activated 
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upstream regulator was tretinoin (i.e. atRA) which was predicted to be moderately 
activated by low-dose atRA, highly activated by high-dose atRA, not activated by DX314 
alone, and very highly activated by DX314 cotreated with low-dose atRA. This analysis 
very strongly supports our hypothesis that DX314 potentiates the effects of atRA, without 
independently acting on RA pathways. Very weak, or in most cases no activity, was 
predicted on the top 20 pathways and upstream regulators identified by DX314 alone which 
also support that DX314 does not have significant off-target activity in the absence of RA. 
DX314 also showed a potentiating effect on low-dose atRA in 75% of the pathways and 
regulators presented also showing strong support of our hypothesis. 
To corroborate the observed gene expression changes, we performed histological 
immunodetection on several respective proteins. Generally, these data show agreement 
with the expected changes based on gene expression effects (Figure 2.3, Figure 3.2). We 
did see paradoxical results in CYP26A1 and CYP26B1 immunodetection, which did not 
appear to be consistent with the mRNA expression changes (Figure 2.4). However, as 
previously discussed, this inconsistency in the relationship between CYP26 mRNA and 
protein expression in the epidermis has been previously documented111,138,139. Although 
this effect has not yet been thoroughly investigated, it has been suggested that RA may 
induce a post-transcriptional mechanism, perhaps by microRNAs, which could influence 
the subsequent translation of CYP26 and resolve this apparent paradox. 
One unexpected, but intriguing discovery in this study is the effect DX314 appears 
to have on RHE barrier function. The initial observation of this effect was discovered upon 
analysis treatment-mediated changes on transepithelial electrical resistance (TEER). TEER 
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informs us of the resistance to ion flow across the tissue, primarily mediated by SG tight 
junctions and the occlusive properties of the SC, which functions as a quantifiable measure 
of barrier integrity. We found that when treated alone, DX314 at the highest dose given 
(1000nM) significantly increases RHE TEER relative to control (Figure 2.6). This contrasts 
with the decrease in TEER by atRA, and no change in TEER by liarozole and talarozole. 
Additionally, liarozole and talarozole both potentiated the barrier disrupting effects of 
atRA, while DX314 appeared to protect the RHE from the expected atRA-induced 
decrease in TEER. 
Histological analysis reveals the significant effect of atRA on epidermal 
morphology including, but not limited to, a significant depletion of the SG which plays a 
major role in barrier function (Figure 2.8, Figure 2.9, Figure 3.2). We saw very little effect 
on epidermal morphology when liarozole or talarozole were used alone, and an effect 
mimicking high-dose atRA when cotreated with low-dose atRA. DX314 on the other hand, 
saw minimal depletion of the SG when cotreated with atRA which is consistent with the 
observed effect on TEER. Immunodetection of the keratin aggregating protein filaggrin, 
which is found in the SG/SC and plays a significant role in epidermal barrier integrity, was 
increased by DX314 in DD RHE  (Figure 3.2). In contrast, FLG staining was greatly 
reduced in atRA treated RHE, and talarozole treated RHE showed no significant change. 
Unfortunately, we were not able to replicate this effect on TEER in healthy RHE 
due to instrument limitations, and attempts to observe significant changes in another 
measure of barrier function, transepithelial water loss (TEWL), were not successful (Figure 
2.7). However, the recent investigation of DX314’s effect in LI RHE did replicate this 
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increase in TEER (Figure 3.6) suggesting this barrier reinforcing effect applies to diseased 
epidermis as well. Despite certain issues, we believe the combination of the healthy and LI 
TEER studies, the RHE histology and immunodetection of barrier components, as well as 
the observation that many cornified envelope precursor family genes of the EDC were not 
affected by DX314 with atRA, but were with atRA alone (Figure 2.10), show compelling 
evidence that DX314 has a protective effect on the barrier function of RHE. Since many 
skin disorders present with a compromised skin barrier, this discovery, which is clearly not 
mediated by a potentiation of atRA, may in fact be a desirable non-specific effect of 
DX314. Although we do not identify, or attempt to elucidate, an explanatory mechanism 
in these studies, further investigation into this should be performed. If the mechanism 
protecting barrier function can be identified, it may lead to a completely novel class of 
dermatological drugs aimed at restoring a compromised skin barrier. 
We currently have several studies underway which will expand upon the findings 
of these studies and prepare for the FDA investigative new drug (IND) application we hope 
to submit. Although we did not see any significant evidence of undesirable off-target 
activity by DX314, we have performed a small experiment showing that DX314 does not 
seem to directly activate RARs. We measured the expression of three, RARE-promoted 
(directly modulated by RAR) genes (STRA6, RBP1, TGM2), and one indirectly RA-
regulated gene (HBEGF), in several treatment combinations of atRA, DX314, and the pan-
RAR antagonist BMS493 (Supplemental Figure 4). We confirmed that atRA modulates 
the expression of these RARE-promoted genes, DX314 does not have any effect alone, but 
potentiates the effect of low-dose atRA, and BMS493 antagonizes these effects indicating 
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they are likely RAR-mediated. We are currently running a large nuclear receptor functional 
assay panel to determine if DX314 displays any activity on these receptors. A lack of 
significant effect by DX314 on these receptors would provide additional evidence that its 
effect is specific to inhibition of CYP26-mediated RA metabolism. Initial results for this 
study show that DX314 has no activity on RAR (α, β and γ), PPAR (α, δ and γ), or LXRβ, 
and can be found in supplemental data (Supplemental Figure 5). 
Another major study we are currently running includes the first in vivo investigation 
of topical DX314. This study utilizes the Rhino mouse model which involves a strain of 
hairless mouse commonly used in the evaluation of retinoid activity on the skin158–160. The 
skin of the Rhino mouse contains keratinized structures (horn-filled utriculi) and dermal 
cysts which are reduced by retinoid treatment. The magnitude of this reduction can be used 
to assess a treatment’s potential to correct dyskeratosis in keratinization disorders. 
Additionally, the study will investigate DX314’s in vivo effect on TEWL to assess any 
changes in barrier function. This study will provide a significant leap in DX314 research 
by providing an in vivo study of the compound which will provide even greater therapeutic 
relevance. 
Moving forward, we will also be running in-depth drug safety assessments, 
developing and testing possible topical formulations, and characterizing the 
pharmacokinetic profile of DX314 as we aim to move into towards clinical trials, and 
ultimately, approval of this promising therapeutic. 
Altogether, we conclude the studies performed in this dissertation provide a 
compelling basis for further IND-enabling studies and development of DX314 as a novel 
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therapy in keratinization disorders. We also show DX314 may have therapeutic relevance 
in the treatment of Darier’s disease, a disorder in which RAMBAs have not been studied 
in the past. Additional studies currently underway will provide significant insight into the 
translational application of this compound and reinforce the body of promising evidence 
suggesting DX314’s therapeutic potential. Finally, evidence showing DX314 may 
reinforce skin barrier function and protect from some undesirable effects of retinoid 
therapy, may provide a completely novel strategy for restoring and protecting a 
compromised skin barrier. It is our hope that work done here will lead to significant 
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Matching molecules: 13 
A 
100nM atRA 
Matching molecules: 54 
B 
Supplemental Figure 2: RhoDGI Signaling Pathway. IPA predicted activity of canonical pathway 
components based on differential expression analysis by RNAseq: (a) 1nM atRA, (b) 100nM atRA, 
(c) 1000nM DX314, (d) 1000nM DX314 + 1nM atRA. Values below each molecule shows respective 






Matching molecules: 0 
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1000nM DX314 + 1nM atRA 








Matching molecules: 15 
Supplemental Figure 3: RAR Activation Pathway. IPA predicted activity of 
canonical pathway components based on differential expression analysis by 
RNAseq: (a) 1nM atRA, (b) 100nM atRA, (c) 1000nM DX314, (d) 1000nM 
DX314 + 1nM atRA. Values below each molecule shows respective fold-change 
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Supplemental Figure 4: Effect of pan-RAR antagonist BMS493 on gene 
expression effects by atRA, RAMBAs. Effects of candidate RAMBAs DX314 
(left column) or DX308 (right column) with, or without, low dose atRA, on 
HBEGF, and RARE-promoted (STRA6, TGM2, RBP1) gene expression compared 
to atRA. All treatments are also done in the presence, or absence, of pan-RAR 
antagonist BMS493. This study was performed in autocrine monolayer cultures of 





Supplemental Figure 5: Nuclear Receptor EC50 Screening 
of DX314, DX308. Performed by Syneos Health using HeLa 
lec2P/9XGAL4 cell lines transfected with expression vector 
for respective nuclear receptor. IA = Inactive. 
Note: This data shows the preliminary data of an ongoing study 
and may not represent the final study results. 
